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Abstract 
The ATP-binding cassette sub-family A member 3 (ABCA3) plays a critical role in 
the lipid metabolism of pulmonary surfactant. Locating on the outer membrane of the 
storage and secretion compartment of surfactant in alveolar type II cells, the lamellar 
bodies (LBs), ABCA3 is responsible for transporting phospholipids from the cytoplasm 
into the LBs. Mutations of ABCA3 were identified from patients suffering from neonatal 
respiratory distress syndrome (RDS) and childhood interstitial lung diseases (chILD). 
Therefore, exploring the functional assays of ABCA3 is in great demand for 
pathophysiology investigation and treatment researching. 
In the present study, wild type and variants of ABCA3 were expressed in A549 
epithelial cells to probe mechanisms for transport activity of ABCA3. To quantify the 
function of ABCA3 alleles, we employed the choline analogue propargyl-Cho. 
Propargyl-Cho was taken up and the resultant phospholipids can be detected using a 
combination of click chemistry, fluorescence derivatization and microscopy to visualize 
and quantify the phospholipid end product. The accumulation of labeled phospholipids 
was time, concentration dependent. The detection of signal was dependent on choline 
kinase to incorporate the label into cellular phospholipids. Miltefosine, another 
substrate of ABCA3 can compete with the transport of propargyl-Cho. Finally, we 
showed that mutations (p.N568D and p.L1580P) in the ATP-binding cassette of 
ABCA3 impaired transport function of propargyl-Cho into intracellular vesicles. 
The present thesis addressed a novel method to assess structure-function 
relationships of ABCA3. 
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1 Introduction 
1.1 Pulmonary surfactant 
Pulmonary surfactant is the lining mixture located on the air-liquid interface of lung 
alveoli space. The most critical function of the surfactant is to lower the surface tension 
therefore enable airway reopening at the end of exhalation. In 1929, Von Neergaard 
detected pulmonary surfactant by measuring pressure-volume curves in pig and dog 
lungs [1]. It was concluded that the lung recoil was mainly surface tension instead of 
tissue elastic resistance. After 30 years, Avery and Mead unraveled the cause of 
respiratory distress syndrome (hyaline membrane disease) was due to pulmonary 
surfactant deficiency [2]. Since the 1990s, surfactant replacement therapy for preterm 
and term neonates suffered from respiratory distress has been proved to be safe and 
efficient [3].  
1.1.1 Synthesis of surfactant lipids 
The human terminal airspace comprises two main epithelium cell types: Alveolar 
type I (ATI) cells and alveolar type II (ATII) cells. ATI cells are major components of 
the alveolar gas-exchange surface. ATII cells act as the surfactant synthesis factory, 
innate immune defender, and healer of lung injury. Morphologically, distinct to the large 
A
. 
B. 
Introduction 
 3  
flat ATI cells, ATII cells are cubic and have lamellar bodies (LBs) inside and microvilli 
on the apical side [4] (Fig. 1).  
In ATII cells, there are two de novo biosynthesis pathways of phosphatidylcholine 
(PC). The CDP - choline (Kennedy) pathway includes phosphorylation of choline to 
phosphocholine by choline kinase (CK), then phosphocholine is transferred into CDP 
- choline by phosphocholine cytidylyltransferase (CDP) and finally turned into 
phosphatidylcholine with the enzyme cholinephosphotransferase (CHPT) (Fig. 2). The 
rate-limiting enzyme in this process is CHTP, inhibition of which could lead to time and 
dose dependent apoptosis on exposed cells [5]. Inhibition of choline kinase by specific 
inhibitor could also inhibit PC synthesis [6]. The diglycerol is supplied by reaction of 
phosphatide phosphatase (PAP) on phosphatidic acid. By remodeling of de novo 
synthesized PC, other choline head group lipids such as lyso-phosphatidylcholine 
(LysoPC) and sphingomyelin (SM) are produced [7, 8].  
Figure 2. De novo pathway. Synthesis of phosphatidylcholine (PC) needs cooperation of a 
series of enzymes in ATII cells. CK: choline kinase, CDP: phosphocholine 
cytidylyltransferase, PAP: phosphatide phosphatase, CHPT: cholinephosphotransferase, 
CTP: cytidine triphosphate; CMP: cytidine monophosphate.  
 
Figure 1. Alveolar epithelial cells. (A) Alveolar type I and type II cells. Surfactant is a thin 
layer of lipids and proteins mixture on the liquid-gas interface of alveolar space. (B) Alveolar 
type II cells. Biogenesis of surfactant starts from ER, routed to Golgi, MVBs and finally stored 
inside LBs. Surfactant secreted from LBs majorly are recycled back into ATII cells routed to 
LYS. ER: Endoplasmic reticulum, Golgi: Golgi apparatus, MVB: Multi vesicular body, LB: 
Lamellar body, LYS: lysosomes. 
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Intriguingly, alveolar type II cells not only synthesis newly phospholipids, but also 
recycle the secreted surfactant lipids directly from alveoli [9-11]. By instilling 
radioactively labeled surfactant lipids into the lungs of rabbits, Jacobs H et al. found 
that about 10% of the surfactant lipids pool in ATII cells were reutilized hourly [12]. The 
percentage of reutilized phosphatidylcholine could reach as much as 95% in ATII cells, 
and the efficiency of reutilization depended on the species of the lipid and possibly the 
age [12, 13]. For example, the reutilization rate of phosphatidylglycerol and 
phosphatidylethanolamine is slower than phosphatidylcholine [14].  
1.1.2 Composition of surfactant 
Lipids compose around 90% of surfactant while the other 10% is surfactant 
proteins. Around 80 – 90% of total lipids in surfactant are phospholipids; the rest are 
cholesterol, triacylglycerols (TAG) and free fatty acids (FFA) in a descending order. Of 
the phospholipids, around 70 – 80% are PC, the rest are phosphatidylethanolamine 
(PE, 12%), phosphatidylglycerol (PG, 10%), phosphatidylinositol (PI, 0.4%), 
lysophosphatidylcholine (LysoPC, 0.3%), phosphatidylserine (PS, 0.1%) and others 
(3%) [15]. The most important PC specie, dipalmitoyl phosphatidylcholine (DPPC, 
16:0/16:0) consists about 50% of the total mass of surfactant, and the rest are 
monoenoic species such as C16:0/18:1 and C16:0/16:1, and dienoic species such as 
C16:0/18:2 [7, 16-18].  
Around 10% of surfactant mass is proteins. Surfactant specific proteins include two 
hydrophilic proteins SP-A (3 – 4%) and SP-D (0.5%), and two hydrophobic proteins 
SP-B (0.1%) and SP-C (0.5%) [19-22]. SP-B and SP-C could accelerate the adsorption 
of mixed up surfactant lipids to the gas-liquid interface, and in certain circumstances 
the hydrophilic protein SP-A could even promote this process [23-25]. Besides related 
to normal surfactant physiologies, SP-A and SP-D also play roles in regulating innate 
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and adaptive immune functions of the host by mediating phagocytosis and 
discriminating against pathogens in vivo and in vitro [26, 27]. 
 
1.1.3 Transport of surfactant between sub organelles 
Mavis. R.D. et al. proved the phospholipids biogenesis in ATII cells mainly 
happened in the endoplasmic reticulum (ER) since more than 60% of phosphatide 
phosphatase enzyme was associated with ER [28]. The localization responsible for 
storing de novo synthesized and recycled surfactant lipids and re-secret surfactant into 
airspace is the lamellar body (LB). It was clarified that the internal transport direction 
of surfactant phospholipids was from high density fraction particles to lower density 
multivesicular bodies (MVB) and finally reach LBs. With phospholipids gradually 
accumulated inside LBs, the phospholipids/protein mass ratio of LBs increased [29-
Figure 3. Lipids and protein composition of pulmonary surfactant. Phospholipids data 
of ATII cells were from the study of Mason and Williams [15].  
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31]. However, the mechanism of sorting and transporting of synthesized 
phosphatidylcholine from ER to LBs is not clear. Either the Golgi apparatus contributes 
to the transportation of PC or not is controversial. Autoradiograph results from 
Chevalier G and Collet AJ showed that the label  [3H] choline colocalized massively in 
the Golgi apparatus zone 30 min after in vivo injection [31]. However, by disassembling 
the Golgi apparatus by brefeldin A and [3H] choline labeling, Osanai K and colleagues 
clarified the transport of phosphatidylcholine from ER to lamellar bodies was a Golgi – 
independent way [32, 33]. Since lamellar bodies do not possess the necessary 
enzymes for surfactant lipids production [28], it is not bold to presume the existence of 
lipids transfer protein or vesicular transportation between ER and LBs. After knocking 
down the START domain-containing protein 10 (STARD10) in mice [34-37], Sui L et 
al. found the saturated phospholipids in LBs decreased thus predicted STARD10 
played a role in phospholipids trafficking [38].  
1.1.4 Lamellar bodies 
Lamellar bodies are the intracellular surfactant pool which store and secret 
assembled surfactant by moving to the apical surface of ATII cells. The diameter of 
LBs varies from 0.1 µm to 2.4 µm. In physiological conditions, LBs are vesicles 
assembled by multiple lipids layers, thus in a shape of ‘onion’ under electron 
microscope.  
Originated from the lysosome, LB shares similarities with its ancestor. According 
to the ATP-dependent process, the internal pH of LBs is below 6.1 measured by 
Chander A. et al. [39]. LBs also contain several proteins or markers the same as 
lysosomes such as acid phosphatase and CD63. LBs store the phospholipids inside, 
meanwhile hold mature SP-B and SP-C that were transported into LBs through the 
Golgi-dependent pathway. Although the specific mechanism of transporting these 
proteins into LBs is not clarified, it could be explained that the super hydrophobic SP-
Introduction 
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B and SP-C tend to enter LBs, which virtually are vesicular multiple lipids layer in 
physiological conditions.  
Besides ATII cells in the lung, LBs were also found existed in the mucosa cells in 
the gastrointestinal tract, epidermal cells in the skin, tongue papillae and mesodermal 
cells in joints. Although the species of lipids inside LBs varies from the location, the 
principal function of LBs in situ is to produce hydrophobic protection [40-48].  
1.1.5 Function of surfactant lipids 
The dominant phospholipid specie in the surfactant is dipalmitoyl 
phosphatidylcholine (DPPC), which composes about 50% of phosphatidylcholine in 
ATII cells [49-52]. DPPC has the palmitic acid on both 1- and 2- positions. At the end 
of expiratory when the lung is at the lowest volume, DPPC could help to lower surface 
tension to less than 10 mN/m, thus reopen the airspace and prevent alveolar edema 
[53]. Although the acidic phospholipids PG and PI are only a minor proportion of 
surfactant, they potentially help to reduce surface tension after mixing up with DPPC 
[54].  
1.2 ABCA3 
ABCA3, short of ATP binding cassette subfamily A member 3, is a lipids 
transporter explicitly located on the outer membrane of lamellar bodies from the ABC 
transporter family. In 2002, ABCA3 was firstly identified by Mulugeta S et al. by 
immunoprecipitation with the antibody of lamellar body membrane protein of 180 kDa 
(LBM180) [55, 56]. With the critical role of ABCA3 in phospholipids transport was 
stated by in vivo and in vitro experiments [57-61], the abnormal function of ABCA3 was 
realized to had a causal relationship with childhood interstitial lung diseases (chILD) 
and RDS.  
1.2.1 ABC transporter family 
Introduction 
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ABC transporters are a group of membrane proteins that exist in eukaryotes, 
bacteria and archaea. By hydrolyzing ATP to ADP, ABC transporters transfer alacrities 
against a concentration gradient across lipid membrane. It’s not exaggerating to name 
ABC transporter family a ‘super family’. To date, 48 ABC transporter genes have been 
identified in the human genome and divided into seven subfamilies. ABC transporters 
share homologous structures: two nuclear tide binding domains (NBDs, bind to ATP or 
ADP), and two transmembrane domains (TMDs) which commonly contain six 
transmembrane α-helix [62-65]. Three conserved motifs are situated in the NBDs: 
Walker A, Walker B and a signature motif C which locates between A and B 
distinguishing ABC transporters from any other ATP binding proteins [66]. Some ABC 
transporters are organized to have full domains of NBDs and TMDs (e.g. ABCA1, 
ABCA3), some possess only one set of the domains (e.g. ABCA5 and 8, ABCG2), few 
others even have extra domains (e.g. ABCC1).  
Substrates of ABC transporters include lipids, ion, drug or drug conjugates, 
peptides, nucleosides and sterols. Due to the indispensable role of ABC transporters 
in physiological states, mutations happening to their coding gene can cause mild to 
severe diseases. For example, Tangier disease (ABCA1), cystic fibrosis (ABCC7), 
Stargardt macular degeneration (ABCA4), Dubin–Johnson syndrome (ABCC2) and 
interstitial lung diseases (ABCA3) [67-75].  
1.2.2 Biogenesis and structure of ABCA3 
ABCA3 gene in the human genome locates on chromosome 16p13.3, includes 80 
kb genomic DNA and codes 1704 amino acids (NM_001089.2) [60, 76]. RNA 
expression of ABCA3 was found in a variety of tissues and organs while exceptionally 
high in lung tissue [77]. Studies from primary ATII cells and transfected cell models 
showed the ABCA3 biogenesis pathway in ATII cells: after synthesized in the 
endoplasmic reticulum (ER), ABCA3 is routed to and modified in Golgi apparatus then 
Introduction 
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sorted to multivesicular bodies (MVB), and finally directed to the outer membrane of 
LBs. After releasing the lipids into alveolar, ABCA3 is recycled into early endosomes 
(EE) and back to MVBs (Fig. 4A) [56, 59, 68, 72, 77-81].  
By site directed mutagenesis of putative N-glycosylation sites in ABCA3, Beers MF 
et al. found N-glycosylation at sites Asn124 and Asn140, close to the N-terminal (Fig. 
5) [81]. Deficient N-linked glycosylation of ABCA3 by inhibition with tunicamycin, or 
substitution of asparagine to glutamine at p.124 and p.140 resulted in ABCA3 being 
retained in ER and misrouted to proteasomes.  
In immunoblots, wild type ABCA3 has two bands simultaneously [61, 82, 83]. In 
the study of Engelbrecht S et al., scientists found N-terminal tagged ABCA3 owned 
only one protein band compared to C-terminal tagged ACBA3, while consistent 
inhibition of protein translation would lead to the fade of the upper band [84]. Then they 
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Figure 4. Biogenesis and 3D structure of ABCA3. (A) Biogenesis of ABCA3. The post-
translational product of ABCA3 was assembled in ER, modified in Golgi and directed to 
MVBs and outer membrane of LBs. (B) 3D structure of ACBA3 on the outer membrane of 
LBs. Conformational change of ABCA3 made it possible to transport lipids from cytoplasm 
to the lumen of LBs. NBD1: nucleotide binding domain 1, NBD2: nucleotide binding 
domain 2. 
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blotted ABCA3 from p.Q215K mutant cells in which ABCA3 was retained in ER; the 
results indicated the mutant protein was lack of lower band. Finally, with 
immunofluorescence it was recognized that ABCA3 protein was cleaved at the N-
terminal inside LAMP3+ vesicles with the protease cysteine. In a later study of the 
same group, the exact cleavage site of ABCA3 was proved to locate after Lys174 in 
the first extracellular loop (Fig. 5) [79].  
Sharing common structures of ABC transporters, ABCA3 contains two NBDs 
facing towards the cytoplasm, two TMDs each consists of 6 transmembrane α-helix 
and 2 extracellular domains (ECDs), facing towards lamellar body lumen. Although due 
to different prediction algorithms the numbers to identify the structure of 12 
transmembrane α-helix and NBDs are slightly different in studies [58, 85-87], it’s 
consensus that each α-helix consists of 20 amino acids and the length of NBD1 and 
NBD2 are 153 and 154 amino acids separately (Fig. 5). Paolini A et al. postulated the 
Figure 5. Ultra-structure of ABCA3. From N-terminal to C-terminal of ABCA3, lying two 
extracellular domains (ECD2 and ECD2), two transmembrane domains, two nucleotide 
binding domains (NBD1 and NBD2). A: Walker A motif, B: Walker B motif, C: signature 
sequence C.  
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NBD1 spanned from aa.569 to aa.721, while NBD2 spanned from aa.1419 to 1572 in 
ABCA3. The region of Walker A and B motif in NBD1 were GHNGAGKT and VLILD, 
while in NBD2 were GFNGAGKT and VIFLD [86]. Besides Walker A and B motifs, in 
each NBD exists Q-, D- and H-loops, which are important among others for ATP 
binding, conformational change and protons shuttling between reactants. [86, 88-90].  
1.2.3 Function of ABCA3 
ABCA3 is key to the biogenesis of full functioning LBs in human lung. Expression 
of ABCA3 in A549 cells or HEK293 cells both resulted in LB-like vesicles inside. While 
silencing of ABCA3 in human ATII cells or rat lung cells lead to aberrant or 
disappearing of LBs [57, 59, 67, 72, 78, 91, 92].  
Located on the outer membrane of LBs, ABCA3 is in charge of transporting a 
variety of lipids such as phosphatidylcholine from cytoplasm into LBs. In ABCA3 
knocked out mice, normal LBs were substituted by abnormal electron dense bodies in 
ATII cells. Meanwhile, lipids mass spectrometry indicated PC and PG in ABCA3 
knocked out lung dramatically decreased compared to normal ones [67]. Similar results 
were concluded from the study of Fitzgerald ML et al., that in ABCA3 null mice more 
than 300 subspecies of PG and several PC lipids were reduced compared to wild type 
[91]. Cheong N et al. found ABCA3 expression increased A549 cells uptake of 
sphingomyelin and cholesterol besides PC [72].  
1.2.4 ABCA3 mutations and related pulmonary diseases 
Since PC, PG and cholesterol are essential components of pulmonary surfactant 
as introduced in Part 1.1.6, the transport function of ABCA3 is indispensable for 
surfactant homeostasis. The fact that ABCA3 null mouse models with disrupted LBs 
and aberrant surfactant components died few hours after birth is a strong proof of the 
point [57, 58, 67, 72, 91]. Electron microscopy of the lung tissue of infants who suffered 
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from severe RDS with ABCA3 homozygous or compound heterozygous mutations 
exhibited altered ultrastructure of LBs [93-97].  
Up to date, more than 200 patients’ originated mutations of ABCA3 gene have 
been identified around the world [98]. The majority of these mutations have a 
phenotype of severe pulmonary surfactant deficiency. Thus patients could only survive 
few hours to few months after birth [96, 99-105]. In the cohort study from Wambach JA 
et al., patients with frameshift or nonsense mutation on both alleles had worse 
outcomes (100% chance to suffer respiratory failure at birth) compared to other 
homozygous or compound heterozygous genotypes (75%) [106].  
ABCA3 mutations are also a major cause of childhood interstitial lung diseases 
(ChILD), also called diffuse parenchymal lung disease (DPLD). The pathology features 
of ChILD are variable and clinical manifestations include tachypnea, hypoxemia, 
crackles, and failure of thriving. [107]. Thus, the non-specific clinical features make it 
difficult to diagnose the disease by physicians. Lipids mass spectrometry analysis of 
broncho-alveolar lavage fluid (BALF) from ABCA3 – deficient ChILD patients showed 
that PC-specie with 30 and 32 carbons and almost all PG species were reduced 
compared to control group [49].  
Genes or proteins involved in ChILD include surfactant protein families (SFTPA, 
SFTPB and SFTPC), ABCA3, thyroid transcription factor 1 (TTF1), methionine-ARNt-
synthetase (MARS), GM-CSF receptors (CSF2RA, CSF2RB), GATA-type transcription 
factor (GATA2), transmembrane protein 173 (TMEM173) and coatomer protein 
complex subunit α (COPA) [108]. ChILD due to ABCA3 mutations has a prevalence of 
about 1.5/million per year [109]. It was prostituted that ABCA3 mutations might be the 
most common cause of genetic surfactant diseases although lack of systematic 
analysis of other inherited causes, since the number of reported cases arises every 
year [110, 111].  
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The ABCA3 genotypes leading to ChILD are commonly compound heterozygous 
mutations of nonsynonymous substitution. A traditional way to classify the type of 
ABCA3 mutations in ChILD is as follows: Type I mutation, also known as trafficking 
mutations, means the genetic variation leads to the misfolding or misrouting of ABCA3. 
Thus it is retained in the upper stream of the intracellular transportation routine, 
typically in the ER. Confocal microscopy of this type of mutant cells showed no mature 
ABCA3+ vesicles, colocalization of ABCA3 with CD63 (another LB marker) 
disappeared, but colocalization of ABCA3 with calnexin (ER marker) existed. 
Examples of such variants are p.Q215K, p.A1046E, and p.G1421R [61, 112-115]. 
Type II mutation, also known as functional mutations, means the mutated ABCA3 
possesses normal folding or processing from ER to the outer membrane of MVBs or 
LBs. However, the majority of this type of mutation locate close to or inside the NBD 
regions and therefore they affect the normal lipid transporting function of ABCA3 by 
influencing the ATP or ADP binding ability of NBDs or interfering with conformational 
changing of the substrate tunnel [61, 87, 112].  In confocal microscopy, the mutated 
ABCA3+ vesicles are colocalized with LBs, however, the volume is much smaller 
compared to WT ABCA3. Lipid components of isolated LBs from cell models were also 
altered [82]. For instance, p.E292V, p.N568D and p.L1580P are type II mutations. Type 
III mutation also referred as compound heterozygous mutations, means combination 
of type I and type II mutations. Patients with type III mutations always resulted in severe 
phenotypes and poor outcomes. For example, the most prevalent mutation of ABCA3, 
p.E292V, which is a type II mutation, was frequently reported to compound interact 
with other type I or II mutations in ChILD patients [98].  
1.2.5 Treatment of ABCA3 mutations related pulmonary disease 
Although the molecular mechanism of surfactant deficiency induced by ABCA3 
mutations has been deeply studied, the specific treatment of this genetic disorder is 
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still not available. In the case reports from physicians, therapeutic strategies of chronic 
ILD such as exogenous surfactant, corticosteroids (either intravenous, oral or 
inhalation), macrolide and hydroxychloroquine always resulted in transient or 
inconstant effects [116-118]. Therefore, superior and specific treatment targeting on 
the etiology of the mutant is urgent to be discovered.  
The drug development of the mutation of CFTR (ABCC7), another ABC transporter 
that is the classical cause of cystic fibrosis due to impaired chloride channel has been 
laboriously and systematically investigated. More than 100,000 small molecules have 
been tested by high-throughput assay for CFTR mutation treatment [119, 120].  The 
effective molecules were classified into two main groups: ‘correctors’ for correcting 
misfolded proteins, such as VX-809 [121, 122]. And ‘potentiators’ for potentiating 
functional defected chloride channels, such as Ivacaftor [123, 124].  
Based on that the structure of ABCA3 sharing similarities with CFTR, Kinting S et 
al. treated A549 cells stably expressing ABCA3 type I or type II mutations with the 
correctors and potentiators used in CFTR treatment [87, 114]. After treatment with 
correctors C13 or C17, immunoblotting of ABCA3-HA from trafficking mutations 
showed two protein bands on the gel, and in confocal microscope ABCA3-HA 
colocalized with CD63 vesicles. To test if the transporting function of corrected ABCA3 
was restored, they half quantified the transport of TopFluor phosphatidylcholine (TopF-
PC) by ABCA3 which was established before [125]. The treatment strategy of 
functional ABCA3 mutations by potentiators also resulted in functional improvement. 
The pioneer experiments gave good examples of finding new therapeutic methods for 
ABCA3 mutations. 
1.2.6 Functional assay of ABCA3 
On the way for treatment research, either by individual testing or high-throughput 
assay of drug libraries, it is essential to establish a reliable functional assay for the 
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lipids transport function of ABCA3. Matsumura Y et al. described the ATP/ADP binding 
and releasing function of NBDs by vanadate-induced radioactive nucleotide trapping 
[61, 78, 112]. This was also used to analyze the ATP hydrolysis function of P-
glycoprotein, ABCA1, ABCC2 and other ABC transporters [126-128].  
In the study of Höppner S et al., fluorescence labeled phosphatidylcholine TopF-
PC wrapped in surfactant like liposomes was utilized as a PC analogue to study the 
transport function of ABCA3 [125]. The advantage of combining TopF-PC, confocal 
microscopy and open source image analyzing software made it convenient for 
application. However, the TopF-PC assay has some short comings. The somewhat 
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bigger size of TopF-PC compared to natural PC and the introduction of labeled 
liposomes into the PC-reutilization pathway made investigation of intracellular PC 
processing rather difficult. 
Jao et al. reported a choline analogue, propargyl-choline (propargyl-Cho) to 
metabolically label phospholipids with choline head via physiological synthesis 
pathway (Fig. 6A). Propargyl-Cho has been successfully applied in mammalian and 
plant cells for the choline metabolism study [129, 130]. Based on those studies we 
established a new assay of choline phospholipids transport by ABCA3. 
  
Figure 6. Propargyl-choline and click reaction of labeled PC. (A) Replacement of choline 
by propargyl-choline (propargyl-Cho) in De novo pathway. Structurally, propargyl-Cho has 
a three-carbon propargyl group (red dot box) on one methyl site of choline. Theoretically, 
propargyl-Cho could be transformed by series reaction of CK, CTT and CHPT into 
phosphatidyl-propargyl-choline. (B) Click reaction. After exposure, cells treated with 
propargyl-Cho were fixed and with the existence of Cu2+ labeled lipids in the cells could 
react with an azide fluorophore (F) and visualized by confocal microscopy together with 
immunofluorescence labeled ABCA3-HA. This figure is cited from Li. Y et al., 2019.   
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2 Aims 
To establish another functional assay for the analysis of choline head 
phospholipids transport function of ABCA3. To determine if the choline analogue 
labeling assay could elucidate the transport function deviation of mutant ABCA3 
protein compared to wild type. To construct a repeatable method to isolate lamellar 
bodies from A549 cells stably expression ABCA3 for subsequent lipidomic and 
proteomic studies. 
  
Zusammenfassung 
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3 Zusammenfassung 
Die häufigste genetische Ursache für interstitielle Lungenerkrankungen im 
Kindesalter sind Mutationen im Gen des Lipidtransporters ABCA3. Dieser intrazellulär 
lokalisierte Transporter ist eine Schlüsselkomponente in der Genese der 
Lamellenkörperchen, dem Transport von Cholin-haltigen Phospholipiden und der 
Produktion von Lungensurfactant. Die Untersuchung und Quantifizierung der ABCA3-
Transportfunktion spielt eine zentrale Rolle bei der Suche nach neuen 
Therapiemöglichkeiten von interstitiellen Lungenerkrankungen aller Altersgruppen. 
Ziel der Arbeit war es eine Methode zu etablieren, die eine in vitro Bestimmung 
Transporterfunktion ermöglicht. 
Dazu wurden die Cholin enthaltenden Phospholipide in ABCA3 stabil 
exprimierenden Zellen mittels Propargylcholin metabolisch markiert. Die so markierten 
Lipide wurden durch die Klickreaktion eines Azid-Fluorophors im konfokalen 
Mikroskop sichtbar gemacht. Eine Quantifizierung der Fluoreszenzintensität nur 
innerhalb der ABCA3+-Vesikeln, zeigte die Cholinphospholipid-Transportfunktion von 
ABCA3 an. Mit dieser Methode konnten wir die Funktionsabweichungen zweier 
krankheitsverursachender Mutationen von ABCA3, p.N568D und p.L1580P, 
quantifizieren. Es fand sich eine gute Übereinstimmung der Ergebnisse dieser 
Methode, die metabolische Markierung der Lipide nutzt, mit derjenigen, die durch 
primär markierte Liposomen gewonnen wurden. 
Somit steht nun eine weitere Möglichkeit bereit, in einem Zellmodell exprimierte 
ABCA3-Mutationen zu untersuchen. 
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4 Material and Methods 
4.1 Materials 
Chemicals 
(+)-Sodium L-ascorbate Sigma-Aldrich, Taufkirchen, Germany 
100% Acetic Acid Applichem, Darmstadt, Germany 
2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-
Tetrazolium-5-Carboxanilide (XTT) 
Sigma-Aldrich, Taufkirchen, Germany 
37% Formaldehyde Merck, Darmstadt, Germany 
Agarose NEEO Roth, Karlsruhe, Germany 
Bovine Serum Albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
Complete Protease Inhibitor Cocktail Roche, Mannheim, Germany 
Copper (II) Sulfate Pentahydrate Sigma-Aldrich, Taufkirchen, Germany 
Diazabicyclooctan (DABCO) Merck, Darmstadt, Germany 
Dimethyl Sulfoxide Sigma-Aldrich, Taufkirchen, Germany 
Dithiothreitol (DTT) Merck Millipore, Burlington, USA 
Ethylenediaminetetraacetate (EDTA) Sigma-Aldrich, Taufkirchen, Germany 
Glycerol Sigma-Aldrich, Taufkirchen, Germany 
Glycine Sigma-Aldrich, Taufkirchen, Germany 
Hydrochloric Acid Merck, Darmstadt, Germany 
LB Agar Merck, Darmstadt, Germany 
LB Broth Merck, Darmstadt, Germany 
LDS ThermoFisher Scientific, Waltham, USA 
Lipofectamine 3000 ThermoFisher Scientific, Waltham, USA 
Lysotracker Blue DND-22 ThermoFisher Scientific, Waltham, USA 
Lysotracker Red DND-99 ThermoFisher Scientific, Waltham, USA 
Methanol Avantor, Gliwice, Poland 
Miltefosine Cayman chemical, Michigan, USA 
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MN58b AOBIOUS, Massachusetts, USA 
N-(2-Hydroxyethyl)-N, N-dimethyl-2-propyn-1-
aminium bromide (Propargyl-choline) 
Jena Bioscience, Thuringia, Germany 
Orthovanadate Sigma-Aldrich, Taufkirchen, Germany 
P3000 reagent ThermoFisher Scientific, Waltham, USA 
Phenazine Methosulfate (PMS) Sigma-Aldrich, Taufkirchen, Germany 
Saponin Roth, Mannheim, Germany 
Sodium Deoxycholate Sigma-Aldrich, Taufkirchen, Germany 
Sodium Dodecyl Sulfate (SDS) Sigma-Aldrich, Taufkirchen, Germany 
Sodium Hydroxide (NaOH) Merck, Darmstadt, Germany 
Sucrose SERVA, Heidelberg, Germany 
Syber Green PCR Master Mix ThermoFisher Scientific, Waltham, USA 
TAMRA-PEG3-Azide Baseclick, Munich, Germany 
Tris Molecular biology grade Applichem, Darmstadt, Germany 
Tris((1-hydroxy-propyl-1H-1,2,3-triazol-4-yl) 
methyl) amine (THPTA) 
Baseclick, Munich, Germany 
Triton-X 100 Sigma-Aldrich, Taufkirchen, Germany 
TWEEN 20 Sigma-Aldrich, Taufkirchen, Germany 
 
Antibody 
Alexa Fluor-488 donkey anti rat ThermoFisher Scientific, Waltham, USA 
Alexa Fluor-488 goat anti mouse Santa Cruz Biotechnology, Texas, USA 
Anti HA-tag rat Sigma-Aldrich, Taufkirchen, Germany 
Calnexin C-20 goat polyclonal IgG ThermoFisher Scientific, Waltham, USA 
CD63 (H-193) rabbit polyclonal IgG Santa Cruz Biotechnology, Texas, USA 
GM130 goat polyclonal IgG Santa Cruz Biotechnology, Texas, USA 
HRP-conjugated β-actin Santa Cruz Biotechnology, Texas, USA 
HRP-conjugated goat anti rabbit ThermoFisher Scientific, Waltham, USA 
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HRP-conjugated goat anti mouse ThermoFisher Scientific, Waltham, USA 
Mouse anti-Stoml 2 Proteintech, Rosemont, USA 
Mouse anti-EEA1 BD Biosciences, New Jersey, USA 
 
Kit 
BCA Protein Assay Kit ThermoFisher Scientific, Waltham, USA 
High Pure RNA isolation Kit Roche, Mannheim, Germany 
peqGOLD Plasmid Miniprep Kit I peQlab, Erlangen, Germany 
Tetro cDNA Synthesis Kit Meridian Life Science, Memphis, USA 
 
Laboratory Instruments 
4000QTRAP AB Sciex, Darmstadt, Germany 
Avanti J-E High Performance Centrifuge Beckman Coulter, Krefeld, Germany 
Biological Safety Cabinets Safe 2020 ThermoFisher Scientific, Waltham, USA 
BioTek™ Eon™ Spectrophotometer ThermoFisher Scientific, Waltham, USA 
Branson 450 Digital Sonifier G. Heinemann Ultraschall und 
Labortechnik, Schwäbisch Gmünd, 
Germany 
Cellometer Nexcelom, Massachusetts, USA 
Centrifuge 5417C Eppendorf AG, Hamburg, Germany 
Centrifuge 5417R Eppendorf AG, Hamburg, Germany 
Chemiluminescence Detection Module Raytest, Baden-Württemberg, Germany 
Consort EV243 Power Supply Merck, Darmstadt, Germany 
Freezer -20 °C Liebherr, Kirchdorf, Germany 
Freezer -80 °C ThermoFisher Scientific, Waltham, USA 
Heraeus Instruments Function Line Kendro Laboratory Products GmbH, 
Germany 
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Heraeus Multifuge 3S+ ThermoFisher Scientific, Waltham, USA 
Incubation Baths 1008 GFL Gesellschaft für Labortechnik, 
Hannover, Germany 
Intas Gel iX Imager Royal Biotech, Brandenburg, Germany 
JA-25.50 Fixed-Angle Rotors Beckman Coulter, Krefeld, Germany 
Liquid Nitrogen Tank German-Cryo, Jücken, Germany  
LSM800 system Carl Zeiss, Oberkochen, Germany 
Minicentrifuge C1301 Labnet International, New Jersey, USA 
Minicentrifuge MCF-2360 LMS CO., LTD, Tokyo, Japan 
Nalgene Cyro Freezing Container ThermoFisher Scientific, Waltham, USA 
Nanodrop ND-1000  ThermoFisher Scientific, Waltham, USA 
New Brunswick EXCELLA E24R Eppendorf AG, Hamburg, Germany 
Optima L-80 XP Ultracentrifuge Beckman Coulter, Krefeld, Germany 
Optima TLX Ultracentrifuge Beckman Coulter, Krefeld, Germany 
ROTANTA 460R Hettich, Tuttlingen, Germany 
SW32Ti Swinging Bucket Rotors Beckman Coulter, Krefeld, Germany 
T-Gradient ThermoBlock ALT, East Lyme, USA 
TLA 110 Beckman Coulter, Krefeld, Germany 
UNIVERSAL 16R (Type 1602) HETTICH, Tuttlingen, Germany 
Vortex Genie 2 Bender & Hobein, Zurich, Switzerland 
Vortex Mixer 7-2020 neolab Migge, Heidelberg, Germany 
 
Disposables 
µ-Slide 8 well ibiTreat Ibidi, Gräfelfing, Germany 
4titude, FrameStar 96 Brooks Life Sciences, Massachusetts, 
USA 
Cell counting chambers Nexcelom, Massachusetts, USA 
Cell scraper SARSTEDT, Nümbrecht, Germany 
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Combitips advanced 5 ml, 10 ml Eppendorf AG, Hamburg, Germany 
CyroPure Tube 1.6 ml mix. Color SARSTEDT, Nümbrecht, Germany 
FALCON 15 ml  Corning, NY, USA 
Microplate, 96 well, F-bottom, clear Greiner Bio One, Frickenhausen, 
Germany 
Optical Adhesive Film ThermoFisher Scientific, Waltham, USA 
Parafilm laboratory film American National Can Co., Chicago, 
USA 
Pipette Tip 1250 µl, 200 µl, 100 µl, 20 µl SARSTEDT, Nümbrecht, Germany 
Safe-Lock Tubes 0.5 ml, 1.5 ml, 2.0 ml Eppendorf AG, Hamburg, Germany 
Single use filter Non-pyrogenic 0.20 µm Sartorius AG, Göttingen, Germany 
Stripette 50 ml, 25 ml, 10 ml, 5 ml  Corning, NY, USA 
Syringe 1 ml Becton Dickinson S.A, Madrid, Spain 
Syringe 50 ml B. Braun, Melsungen, Germany 
TC-Platte 6 / 96 Well, Cell +, F SARSTEDT, Nümbrecht, Germany 
Tube 10 ml 100x16PP+Cap YLW SARSTEDT, Nümbrecht, Germany 
 
Cell types 
A549 DSMZ, Braunschweig, Germany 
 
Cell culture medium and materials 
12 well flat bottom cell culture cluster Corning, NY, USA 
Dulbecco’s Phosphate Buffered Saline Sigma-Aldrich, Taufkirchen, Germany 
Flask T75, T25 Corning, NY, USA 
GlutaMAX - I (100X) ThermoFisher Scientific, Waltham, USA 
Opti-MEM (1X) ThermoFisher Scientific, Waltham, USA 
Sodium pyruvate 100mM (100X) ThermoFisher Scientific, Waltham, USA 
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TC Dish 150, Standard SARSTEDT, Nümbrecht, Germany 
Tissue Culture Dish 100 x 20 mm Corning, NY, USA 
Trypsin - EDTA solution Sigma-Aldrich, Taufkirchen, Germany 
 
Western Blot materials 
Novex Sharp Pre-Stained Protein Standard ThermoFisher Scientific, Waltham, USA 
Novex, XCell II Blot Module ThermoFisher Scientific, Waltham, USA 
NuPAGE 3-8% Tris-Acetate Gel 10 well ThermoFisher Scientific, Waltham, USA 
NuPAGE 3-8% Tris-Acetate Gel 12 well ThermoFisher Scientific, Waltham, USA 
NuPAGE Transfer Buffer (20X) ThermoFisher Scientific, Waltham, USA 
PVDF membrane Millipore, Billerica, USA 
Tris-Acetate SDS Running Buffer (20X) ThermoFisher Scientific, Waltham, USA 
 
Buffers and Solutions 
RIPA (Radioimmunoprecipitation assay) buffer 
Tris 50 mM 
SDS 0.1 % (v/v) 
Triton-X 100 1 % (v/v) 
EDTA 5 mM 
NaCl 0.15 M 
Sodium deoxycholate 0.5 % 
Complete protease inhibitor cocktail 1 x 
pH 8.0 
 
TBS-T 
Tris 50 mM 
NaCl 0.15 M 
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Tween 20 0.1 % (v/v) 
pH 7.5 
 
TAE buffer (10x) 
Tris 0.4 M 
Glacial acetic acid 0.2 M 
EDTA 0.01 M 
pH 8.5 
 
PBS-Glycine 
Tris base pH 8.5 0.4 M 
Glacial acetic acid 0.2 M 
EDTA 0.01 M 
 
Mounting media 
Glycerol 90% (v/v) 
DABCO 2% (w/v) 
 
Immunofluorescence (IF) buffer 
BSA 3% (w/v) 
FBS 3% (w/v) 
 
Immunofluorescence – Saponin (IF-S) buffer 
BSA 3% (w/v) 
FBS 3% (w/v) 
Saponin 0.5% (w/v)  
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PBSBS washing buffer 
BSA 0.01% (w/v) 
Saponin 0.1% (w/v) 
 
CuAAC reaction Buffer 
BSA 0.01% (w/v) 
Saponin 0.1% (w/v) 
Sodium ascorbate 1.2 mM 
THPTA 128 µM 
TAMRA-Azide 20 µM 
CuSO4 1 mM 
 
Sucrose Tris buffer 
Tris 20 mM 
Sucrose 1 M 
pH 7.3 
 
DAPI nuclear staining buffer 
DAPI 0.1 µg/ml 
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4.2 Methods 
4.2.1 Site directed mutagenesis 
Transposon vector contains ABCA3 template DNA (pT2/HB-CMV-hABCA3-HA-
PGK-Puromycin) was from the study of Wittmann, T et al. [131]. p. N568D (c. 2886A>G; 
CAA/CGA) or p.L1580P (c.5923T>C; CTG/CCG) point mutations were introduced into 
the template with Q5® Site-Directed Mutagenesis (SDM) Kit. Forward and reverse 
primers of these two mutations were listed as in Table 1. According to the SDM kit 
protocol, a 25 µl reaction system containing 25 ng template DNA, 0.5 µM forward and 
reverse primers and nuclease-free water were mixed up thoroughly. Routine PCR 
cycling condition of the reaction system: initial denaturation at 98°C for 30 sec, 25 
cycles of denaturation (98°C, 30 sec) – annealing (Ta of target primers, 30 sec) – 
extension (72°C, 5 min 45 sec), and final extension at 72°C for 2 min. Treat 1 µl of 
PCR product with kinase, ligase and Dpnl (KLD) enzyme mix (provided in the kit) at 
room temperature for 5 min to digest template DNA.  
For transformation, add 5 µl of KLD mix into a tube of 5-alpha Competent E. coli 
cells, mix thoroughly and incubate on ice for 30 min. Then the mixture was processed 
to heat shock at 42°C for 30 sec and cooling down on ice for 5 min. Add SOC medium 
to the mixture and shake (250 rpm) for 60 min at 37°C for amplification.  Spread 50 µl 
of amplified cells on the selection lysogeny broth (LB) agar plate (Ampicillin 100 µg/ml) 
Table 1. Point mutagenesis primers 
ABCA3-mutation Forward primer (5’-3’) Reverse primer (5’-3’) 
p. N568D GCTGGGCCACGACGGTGC
CGG 
AGGACGGTGATCTGTCCC
TCGTACAG 
p. L1580P TGTGAGGCCCCGTGCACC
CGG 
CTCCTCCATGCTGTGGGA
GG 
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and incubate overnight. For each mutation, pick 10 clones and incubate overnight with 
6 ml Ampicillin – LB medium in falcons.  
4.2.2 Plasmid preparation 
Centrifuge transformed E. coli cells in the falcon down at 4600 g, at 4°C for 15 min. 
Isolate DNA with peqGOLD Plasmid Miniprep Kit I according to the instruction. Briefly, 
resuspend bacterial pellet with 250 µl Solution I/RNase A, add the same amount of 
Solution II, mix carefully until the lysate get cleared and let stand 2 min in room 
temperature. Next, neutralize the lysate by adding 350 µl Solution III in the kit which 
will immediately form a white flocculent precipitate. Centrifuge the mixture at 10.000 g, 
10 min. Load the clear supernatant to a new DNA column in a collection tube. 
Centrifuge the device for 1 min at 10.000 g and discard the liquid. Then add 500 µl PW 
buffer once, 750 µl DNA wash buffer twice for in total three times of wash. Between 
each wash step, centrifuge for 1 min at 10.000 g.  After wash, dry the column matrix 
by centrifuge the collection tube again at 10.000 g for another 2 min. Discard the tube 
and insert the column into a fresh 1.5 ml centrifuge eppi, add 50 µl elution buffer and 
centrifuge at 5000 g to elute DNA.  Measure the DNA concentration with Nanodrop.  
4.2.3 Agarose gel electrophoresis 
Add 1 g agarose in 105 ml TBE buffer in 250 ml wide-mouth flask. Heat the mixture 
up in microwave at 800 w for 3 min 30 sec. Carefully handle the heated flask with 
insulation gloves to flowing water until the mixture cooling to hand warm. Add 15 µl 
ethidium bromide solution and mix gently. Resemble UV-transparent tray, two end 
gates and a comb together, pour the cooled down liquid into the system and stand in 
room temperature for 1 hour until firm gel formed. In each electrophoresis, 4 µl 1 kb 
DNA ladder was loaded together with probes. Electrophoresis setting: 120 V, 110 mA, 
20 W, 45 to 50 min.  
4.2.4 Sequencing 
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Premix 500 ng purified plasmid DNA with 5 µl of 25 ng/µl pT2/HB-CMV-hABCA3-
HA-PGK-Puromycin template DNA. Add 5 µl of 5 µM sequencing primer (Table 2) into 
the sample. All the sequencing was done by Eurofins Genomics Germany GmbH.  
4.2.5 Transfection and single clone generation 
Human A549 cells were seeded 200,000 cells/ml in 6-well plate and maintained at 
37°C and 5% CO2. After 24 hours (or cells reach 80% confluency), mix 7.5 µl 
Lipofectamine 3000 reagent in 125 µl OptiMEM in microcentrifuge tube A. In tube B, 
prepare 4 µg DNA (2857.14 ng plasmid with confirmed sequence, 1142.86 ng 
transposase SB100) and 8 µl P3000 reagent in 125 µl OptiMEM. Mix the reagents in 
tube A and B by pipetting and incubate at room temperature for 5 min. Evenly distribute 
the mixed reagents on the cells. After 48 hours change the medium to puromycin 
containing RPMI to select successfully transfected cells. Change fresh medium every 
four to five days until un-transfected cells were dead. Harvest transfected cells and 
Table 2. Sequencing primers 
SeqPrimer  
CMV-Forward 5’-CGCAAATGGGCGGTAGGCGTG-3’ 
SeqABCA3#1 5’-AGCACCCCTTCAACCAC-3’ 
SeqABCA3#2 5’-TCGCCATCTCTACCATC-3’ 
SeqABCA3#3 5’-GGACGGGCATACATCAG-3’ 
SeqABCA3#4 5’-GGGGCATCCATCACCAC-3’ 
SeqABCA3#5 5’-ACGCCTCCATTGTGGTC-3’ 
SeqABCA3#6 5’-GCGCCTACCTCATCCTG-3’ 
SeqABCA3#7 5’-GCCACATGCCAACAAGC-3’ 
HA Seq forward 5’-CCTTGACCCTGGAAGGTGCC-3’ 
PKG Puro forward 5’-CTTCGCCGCTACCCTTGTGG-3’ 
PKG Puro reverse 5’-CCCCTCGAGGCTAGC-3’ 
M13-RP 5’-CAGGAAACAGCTATGACC-3’ 
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seed 1 cell/well in 96-well plates. Amplify the cells with single colony developed in 12-
well plates, 6-well plates, T25 and T75 flasks consistently.  
4.2.6 Cell culture 
Transfected A549 cells were incubated in RPMI 1640 medium supplemented with 
10% fetal calf serum (FCS) and 0.02% puromycin. Wash cells with PBS. Then, treat 
cells with 1X Trypsin-EDTA for cell detachment. Cells were incubated at 37°C and 5% 
CO2 until reached 90% confluency for downstream use. 
4.2.7 BCA assay 
Collect cell sample in 1.5 ml Eppi, centrifuge at 300 g for 5min. Discard the 
supernatant and wash cell pellets twice with PBS, then store the pellets in -20°C or 
resuspend in 100 µl RIPA buffer with 1X proteinase inhibitor complex on ice for 30 min. 
Then centrifuge the cell lysate for 30 min at 4000 g, 4°C and collect the supernatant. 
Dilute the protein sample with the same volume of RIPA buffer. Then add 12.5 µl of 
BCA protein standard (prepared in RIPA buffer according to the manufacture protocol) 
and diluted sample in duplicates in 96-well-plate. In each well, add 100 µl of mixed 
BCA assay buffer (reagent A: B, 50:1) then incubate at 37°C for 30 min. The 
concentration of protein was measured with a spectrometer at 562 nm.  
4.2.8 Western blot 
Western blot probes were prepared by mixing 15 µg protein with 10% DTT, 1X 
LDS and added up with distilled water to a final volume of 25 µl. Then the probes were 
heated up to 70°C for 10 min to reduce disulfide bonds. In the meantime, prepare 1X 
Tris-Acetate running buffer and 3-8% Tris-acetate gel in a prepared chamber. Add 7 µl 
of pre-stained protein standard and heated samples in the pockets carefully and run at 
150 V, 125 mA for 80 min. During gel running, activate PVDF membrane by rinsing in 
98% methanol for 1 min. Blotting was done in a wet-transfer module (XCell II Blot 
Module) under 125 v, 220 mA at 4°C for 120 min. Block blotted membrane in 5% defat 
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milk in TBS-T buffer for at least 30 min. Anti - ABCA3-HA (rat), EEA1 (mouse), 
Calnexin (goat), GM130 (goat) and Stoml2 (mouse) first antibodies were diluted 1:1000 
in 5% milk and could be used repeatedly for 10 times. Anti – β-actin HRP conjugated 
(mouse) antibody was diluted 1:10000. Secondary antibodies such as anti – rat HRP 
conjugated (donkey), anti – mouse HRP conjugated (goat) and anti – goat HRP 
conjugated (mouse) were diluted 1:10000 freshly in 5% milk in single experiments. 
Incubating of the membranes with first antibodies for 120 min at room temperature or 
overnight at 4°C, and secondary antibodies for 1 h in room temperature. After each 
incubation, wash the membrane with 3 times of TBS-T, 5 – 10 min each. Develop the 
membranes with Western Blot enhancer in an illumination detector. All the images of 
western blot were analyzed with ImageJ. 
4.2.9 cDNA synthesis 
RNA of cultured cells was isolated with RNA isolation kit according to the protocol. 
Briefly, cells pellets were resuspended in 600 µl of 66.7% lysis buffer in PBS and 
thoroughly mixed by vortex. Assemble high pure filter tubes, add the mixed sample to 
the filter tube and centrifuge at 8000 g for 15 s. Discard the liquid on the bottom, add 
10 µl DNase I and 90 µl DNase incubation buffer and incubate for 15 min at room 
temperature. Then add 500 µl wash buffer I to the filter tube and centrifuge at 8000 g 
for 15 s. Discard the liquid then wash twice with wash buffer II, dry the filter tube by a 
final centrifuge at 13000 g for 2 min. Elute the RNA with 50 µl elution buffer and 
measure the concentration with Nanodrop.  
cDNA was synthesized according to Tetro cDNA synthesis kit protocol. Mix 5 µg 
target RNA, 1 µl random hexamer, 1 µl dNTP, 1 µl RNase inhibitor, 1 µl reverse 
transcriptase and add up with DEPC-treated water to a final volume of 20 µl. Incubate 
the samples at 25°C for 10 min followed by 45°C for 30 min, then at 85°C for 5 min 
and chilled at 4°C.  
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4.2.10 Quantitative polymerase chain reaction 
Prepare paired primer mix of 25 µM forward and reverse primer. Then add 0.32 µl 
primer mix, 4 µl cDNA (1:5 diluted), 10 µl Syber Green Master mix and 5.68 µl ddH2O 
to 96-well plates. HRPT1 was set as internal reference. Primers of qPCR were listed 
in Table 3. Run qPCR on an ABI 7900HT cycler with the standard curve from previous 
study [83, 132]. mRNA expression level was analyzed with ∆∆Ct method. The 
expression level of mock cells was set as blank and the data from mutants were 
compared to wild type ABCA3. 
4.2.11 Propargyl-choline treatment 
1 mg of Propargyl-choline (propargyl-Cho) was purchased from Jena Bioscience. 
Add 156 µl of PBS to prepare a 50 mM stock solution of propargyl-Cho. Seed 
transfected A549 cells 200,000 cells/well in 8-well µ-slides and incubate overnight at 
37°C and 5% CO2 until reach 80% confluency. To treat cells with propargyl-Cho, cool 
the cells down at 4°C for 15 min. Dilute stock solution with ice cold OptiMEM to target 
concentration freshly before each experiment. Remove medium on the cells and pulse 
chase with 250 µl of propargyl-Cho at 4°C. After 30 min, replace propargyl-Cho with 
room temperature OptiMEM and incubate at 37°C. In concentration dependent tests, 
cells were treated with 0, 10 µM, 50 µM, 125 µM and 250 µM propargyl-Cho for 24 h. 
In time dependent experiments, cells were treated with same concentration (125 µM) 
of propargyl-Cho for different time period. To explore if single mutation of ABCA3 would 
lead to aberrant lipids transport function of ABCA3, p.N568D, p.L1580P and WT – 
Table 3. qPCR primers 
Gene name Forward primer (5’-3’) Reverse primer (5’-3’) 
ABCA3 CATGGTCAGCACCTTCTTC
A 
TTCTGGCTCAGAGTCATCC
A 
HRPT1 GCTGACCTGCTGGATTAC TGCGACCTTGACCATCTT 
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ABCA3 – HA expressing A549 cells were treated with the same concentration of 
propargyl-Cho for same time period. 
4.2.12 Inhibitors 
To characterize if the ABCA3 transportation of propargyl-Cho labeled lipids 
dependent on ATP consuming, cells pulse chased with 125 µM propargyl-Cho for 30 
min were treated with 12.5 mM orthovanadate for 2 h and incubated for another 22 h 
consistently. To understand the lipids synthesis and transportation during the 
metabolic labeling process, cells were treated with 10 µM MN58b or 10 µM Miltefosine 
diluted in dimethyl sulfoxide (DMSO) at 0 h or 12 h after incubation with propargyl-Cho. 
Cells were washed gently with 37°C PBS for 3 times after inhibition then incubated in 
OptiMEM until harvested in washout experiments.  
4.2.13 Immunofluorescent staining 
Fixation and permeabilization of cells and immunostaining of ABCA3-HA protein 
were done according to established protocol [114, 115]. Briefly, wash cells twice with 
200 µl PBS and fix with 3.7% formaldehyde for 20 min, then remove formaldehyde and 
quench the fixation by incubating with PBS-Glycine (0.1 M) for 10 min. Incubate cells 
with 150 µl 1% saponin to permeabilize cell membranes for 5 min and wash 3 times 
with PBSBS washing buffer, 5 min each. Then incubate cells with IF-S buffer for 30 
min to block unspecific antigens. Cells were incubated with 1:200 diluted first antibody 
(anti-HA from rat) for 1 h and secondary antibody (Alexa-Fluor 488 donkey anti rat) for 
30 min after blocking. Stain cell nuclei with DAPI for 20 min.  
4.2.14 Click reaction 
Prepare 40 mM 5-TAMRA-PEG3-Azide and 200 mM THPTA stock solution in 
DMSO. Prepare 100 mM CuSO4 and 0.25 M sodium ascorbate stock solution in ddH2O. 
Mix CuAAC reaction system freshly: 1966.2 µl PBS containing 0.01% BSA and 0.1% 
saponin, 9.6 µl sodium ascorbate (final concentration: 1.2 mM), 1.28 µl THPTA (final 
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concentration: 128 µM), 1 µl 5-TAMRA-PEG3-Azide (final concentration: 20 µM) and 
20 µl CuSO4 (final concentration: 1 mM). After nuclei staining, incubate cells with 240 
µl of the mixture for 30 min in dark. Then wash 9 times (5 min each) with wash buffer 
and mount with mounting buffer. Store the samples at 4°C.  
4.2.15 Imaging 
A Carl Zeiss LSM800 system was used for all confocal imaging. To start, open 
‘ZEN’ software and select channels match the fluorophores in cells. For propargyl-Cho 
analyzing, TAMRA (excitation: 561 nm, red), AF488 (excitation: 488 nm, green) and 
DAPI (excitation: 405 nm, blue) tracks were selected. In every independent experiment, 
laser power, pinhole, digital offset and digital gain for AF488 and DAPI channels could 
be adjusted for better image, while settings of TAMRA should be unchanged once 
settled at the beginning of that experiment. To analyze the fluorescence intensity of 
labeled lipids in ABCA3+ vesicles, three Z-stacks of 5 slices (0.4 µm interval) were 
composed in one well. The image size of the snaps and Z-stacks was 1024 x 1024 
pixels. All the experiments were performed in duplicates and repeated for three times.  
4.2.16 Fluorescence intensity analyzing 
Fiji software and a Fiji-plugin ‘Particle_in_Cell-3D’ developed by Torrano AA et al. 
[133] were utilized for fluorescence intensity analyzing of Z-stacks [87, 114, 125].  After 
open a Z-stack file with Fiji, split the channels and run the first macro ‘vesicles.ijm’ to 
generate ‘vesicles.tiff’ from green channel and ‘lipids.tiff’ from red channel. Adjust the 
brightness/contrast of ‘vesicles.tiff’ until the edge of vesicles was sharp, select 20 
random vesicles with oval tool as region of interest (ROI). To analyze the fluorescence 
outside of the vesicles, 20 ROIs of size 1 µm x 1 µm were draw with rectangular tool 
on ‘vesicle – nucleus’ merged images, the ‘lipids’ channel was not included to avoid 
bias. The ROIs out of vesicle should be draw in cells within ABCA3+ vesicles but 
without overlapping with nucleus or ABCA3+ vesicles. Fig. 7 gives an example of ROI 
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selection. Afterwards, fluorescence intensity was analyzed by running the second 
macro ‘Particle_in_Cell-3D_v4.ijm’ on ‘lipids.tiff’. During this process, set the 
‘background to be subtracted value’ to 0. Required data was analyzed in Excel.  
4.2.17 Cytotoxicity assay 
The effect of propargyl-Cho and inhibitors on cell viability was tested with XTT 
assay [83, 131]. Dilute cells to 500,000 cells/ml in phenol red free RPMI supplemented 
with 10% FCS. Seed 100 µl of diluted cells in 6 replicates in 96-well plates and incubate 
overnight. Then thaw prepared XTT solution aliquot (1 mg/ml in phenol red free RPMI 
medium) in 37°C water bath. Add 1.25 µl 100 mM PMS (N-methyl-dibenzopyrazine 
methylsulfate) solution (0.0153 g of PMS in 500 µl of PBS) in 5 ml warmed up XTT 
solution and mix well by pipetting. Then put 50 µl/well of mixed solution on the cells 
immediately after preparation and incubate at 37°C for 30 min, light proofing. 
Absorbance was measured at OD490 nm with a spectrometer and the background of 
96-well plates (OD650 nm) was subtracted.  
Figure 7. Region of interest (ROI). (A) Ten ROIs inside vesicles were marked with red 
and elliptical. The rules of ROI selection followed the description of Höppner et al. The edge 
of each ROI should overlay with the outline of the vesicle. (B) Ten ROIs out of vesicles 
(white, square) were marked as example. Scale bar: 10 µm. The figures were cited from Li 
Y et al., 2019. 
A. 
 
B. 
 
Materials and Methods 
 36  
4.2.18 Lipids Mass-spectrometry 
To ensure the incorporation of propargyl-Cho into choline head phospholipids, 
cells were treated with or without 100 µM propargyl-Cho for 30 min in 4°C and incubate 
in OptiMEM at 37°C for another 24 hours. Cell pellets were extracted by methanol 
including 1-tridecanoyl-2-hydroxy-sn-glycero-3-phosphocholine and 1,2-dimyristoyl-
sn-glycero-3-phosphocholine (Avanti Polar Lipids, Alabaster, USA) as internal 
standards. With liquid chromatography coupled to a triple quadrupole mass 
spectrometer (1200 HPLC Agilent, Waldbronn, Germany coupled to 4000QTRAP 
Sciex, Darmstadt, Germany), a flow-injection analysis was performed with the mobile 
phase of 76% isopropanol, 19% methanol and 5% water and the flow rate of 240 
µL/min. Fragments of phosphatidylcholines (m/z = 184 Da) or propargyl-Cho (m/z = 
208 Da) were detected in precursor-ion-scan and mass transitions were given in Table 
3. Analyzed compounds: diacyl-phosphatidylcholines (PC.aa.Cxx.y), sphingomyelins 
(SM.C18.1.Cxx.y) and acyl-lyso-phospholipids (lyso.PC.a.Cxx.y). Cxx.y stands for lipid 
side chain; xx and y indicate the number of carbon atoms and double bonds, 
respectively. This approach was not appropriate to specify the site of the double bonds 
and the arrangement of carbon atoms inside chains of the fatty acid molecule.  
Table 4. Mass transitions for propargyl-Cho species 
Name Q1/Q3 
phosphatidylcholines 
Q1/Q3  
phosphatidyl-propargyl-Cho 
lyso.PC.a.C14.0 468.300 / 184.000 492.300 / 208.000 
lyso.PC.a.C16.0 496.300 / 184.000 520.300 / 208.000 
lyso.PC.a.C18.2 520.300 / 184.000 544.300 / 208.000 
lyso.PC.a.C18.1 522.300 / 184.000 546.300 / 208.000 
lyso.PC.a.C18.0 524.300 / 184.000 548.300 / 208.000 
SM.C18.1.C14.0 675.500 / 184.000 699.500 / 208.000 
SM.C18.1.C16.1 701.500 / 184.000 725.500 / 208.000 
SM.C18.1.C16.0 703.500 / 184.000 727.500 / 208.000 
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SM.C18.0.C16.0 705.500 / 184.000 729.500 / 208.000 
SM.C18.1.C18.2 727.600 / 184.000 751.600 / 208.000 
SM.C18.1.C18.1 729.600 / 184.000 753.600 / 208.000 
SM.C18.1.C18.0 731.600 / 184.000 755.600 / 208.000 
SM.C18.1.C20.2 755.600 / 184.000 779.600 / 208.000 
SM.C18.1.C20.1 757.600 / 184.000 781.600 / 208.000 
SM.C18.1.C20.0 759.600 / 184.000 783.600 / 208.000 
SM.C18.1.C22.2 783.600 / 184.000 807.600 / 208.000 
SM.C18.1.C22.1 785.600 / 184.000 809.600 / 208.000 
SM.C18.1.C22.0 787.600 / 184.000 811.600 / 208.000 
SM.C18.1.C24.2 811.700 / 184.000 835.700 / 208.000 
SM.C18.1.C24.1 813.700 / 184.000 837.700 / 208.000 
SM.C18.1.C24.0 815.700 / 184.000 839.700 / 208.000 
SM.C18.1.C26.2 839.700 / 184.000 863.700 / 208.000 
SM.C18.1.C26.1 841.700 / 184.000 865.700 / 208.000 
SM.C18.1.C26.0 843.700 / 184.000 867.700 / 208.000 
PC.aa.C30.0 706.500 / 184.000 730.500 / 208.000 
PC.aa.C32.1 732.600 / 184.000 756.600 / 208.000 
PC.aa.C32.0 734.600 / 184.000 758.600 / 208.000 
PC.aa.C34.3 756.600 / 184.000 780.600 / 208.000 
PC.aa.C34.2 758.600 / 184.000 782.600 / 208.000 
PC.aa.C34.1 760.600 / 184.000 784.600 / 208.000 
PC.aa.C34.0 762.600 / 184.000 786.600 / 208.000 
PC.aa.C36.4 782.600 / 184.000 806.600 / 208.000 
PC.aa.C36.3 784.600 / 184.000 808.600 / 208.000 
PC.aa.C36.2 786.600 / 184.000 810.600 / 208.000 
PC.aa.C36.1 788.600 / 184.000 812.600 / 208.000 
PC.aa.C36.0 790.600 / 184.000 814.600 / 208.000 
PC.aa.C38.6 806.600 / 184.000 830.600 / 208.000 
PC.aa.C38.5 808.600 / 184.000 832.600 / 208.000 
PC.aa.C38.4 810.700 / 184.000 834.700 / 208.000 
PC.aa.C38.3 812.700 / 184.000 836.700 / 208.000 
PC.aa.C38.2 814.700 / 184.000 838.700 / 208.000 
PC.aa.C38.1 816.700 / 184.000 840.700 / 208.000 
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PC.aa.C38.0 818.700 / 184.000 842.700 / 208.000 
 
4.2.19 Cell homogenization 
WT ABCA3-HA A549 cells from sic of 150 mm culture dishes (around 108 cells in 
total) were washed 3 times with room temperature PBS. Rinse cells in ice cold PBS 
containing 1X proteinase inhibitor complex, 1 ml/dish. Following steps were all on ice 
or in a cold room to chill samples. Carefully detach cells off the wall by scraping and 
gather cell suspensions in a 10 ml falcon. Pellet the cells down by centrifuge at 300 g 
for 10 min (4°C) and resuspend cells in 2 ml of 1 M Sucrose-Tris buffer (1 X PI, pH 7.3) 
by pipetting up and down with a tip-cut pipette. Avoid of air bubbles formation.  
To homogenize cells by nitrogen cavitation, clean the vessel and micro stir bars 
with distilled water. After the sample outlet was tightly locked, transfer well suspended 
cells into the vessel. Set the vessel firmly on a stirrer with a proper stirring speed, close 
the cap and tighten the gas inlet and outlet valves. Afterwards, pressurize the vessel 
with nitrogen gas to 800 psi (pounds per square inch) and equilibrate for 10 min. Open 
the sample outlet valve gradually and collect the drops of cell lysates with a new falcon.  
All the sonification was conducted on ice. Sonicate cells in 1 M Sucrose-Tris buffer 
for 3 times of 2 sec pulse, 30 sec pause and 20% amplitude. Incubate cell lysates with 
5% formaldehyde for 20 min. Get rid of unbroken cells or big debris by centrifuge at 
1000 g for 10 min. The post nuclear supernatant (PNS) was diluted with 1 M Sucrose-
Tris buffer until the total volume of PNS reached 5 ml. Save 0.5 ml PNS for Bradford 
assay and western blot, and the rest 4.5 ml for sucrose gradient LBs isolation. 
4.2.20 Mark lamellar bodies with Lysotracker Red 
To prepare samples for fluorescence activated lamellar bodies sorting, WT 
ABCA3-HA cells were cultured in 150 mm culture dishes until 90% confluences. 
Prepare 100 nM Lysotracker Red (LTR) in 37°C DMEM (1 µl of 1 mM LTR stock 
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solution in 10 ml DMEM). Incubate cells with 15 ml of 100 nM LTR or merely medium 
(control) at 37 °C, 5% CO2 for 1 h then wash out LTR with PBS. Fixing cells with 3.7% 
formaldehyde, statin ABCA3-HA with anti – HA antibody. Verify the uptake of LTR into 
LBs by confocal microscope.  
4.2.21 Lamellar body isolation 
Protocol for lamellar body isolation was improved from previous studies. Briefly, 
add 3.5 ml PNS from homogenization on the bottom of a new 30 ml ultracentrifuge 
tube. On top of PNS, add 1 ml of 0.8, 0.7, 0.6, 0.5, 0.4 and 0.3 M sucrose sequentially. 
Finally, pipette 0.5 ml 0.2 M sucrose solution on top. Avoid of bubbles or vibration in 
the process. After balancing, samples were centrifuged for 15 min at 138 g and 4 h at 
80428 g without interval in between. Collect fraction 1 to 10 from top to bottom with 
fine tips, 1 ml per fraction. 
4.2.22 Statistical analysis 
Rough data from individual experiments were anazyed with Microsoft Excel and 
further processed with Prism 8. One- or Two-way ANOVA and t-test were used in 
grouped data analyzing. For multiple comparisons in two-way ANOVA, Tukey, Dunnett 
or Sidak correction test were conducted.  
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5 Results 
5.1 Establish an assay to probe the phosphatidyl-choline transport function of 
ABCA3 
5.1.1 Construction of ABCA3-HA stable expressing cells 
Western blot and qPCR were used to confirm the successful transfection and 
stable expression of ABCA3-HA in A549 cells. Similar to WT, N568D and L1580P 
A. 
 
B. 
 
C. 
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ABCA3-HA have double bands (190 and 170 kDa) on western blot (Fig. 8A). Among 
all candidates, the ratio of cleaved (lower) to non-cleaved (upper) bands of clone 3 of 
N568D and clone 5 of L1580P kept the same level as WT (Fig. 8B). Meanwhile, these 
two clones showed stable mRNA expression in repetitive experiments (Fig. 8C). To 
certify if the mutated protein reaches LBs, colocalization of ABCA3-HA and CD63, the 
lysosome marker, was examined by double immunostaining. In confocal, the size of 
D. 
 
Figure 8. ABCA3-HA stable expressing A549 cells. (A) Western blot. For each mutation, 
5 clones of single cell colony were cultured and verified the stable expressing of ABCA3-
HA by immunoblotting. WT ABCA3-HA has two bands on western blot. ß-actin (42 kDa) 
was set as reference protein. (B) Ratio of lower to upper band intensity on western blot. 
Images of western blot were analyzed by ImageJ and brightness/contrast was adjusted if 
necessary. Results of three repeated experiments were showed in bars (mean with SEM). 
(C) mRNA expression level of clones. The mRNA expression of WT and clones of mutation 
were compared to mock. (D) Colocalization of ABCA3-HA with CD63. Similar to WT, The 
ABCA3+ vesicles of N568D and L1580P were well oval or round-shaped and colocalized 
with CD63. The figures are cited from Li. Y et al., 2019 and Susanna et al., 2019. 
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ABCA3+ vesicles of N568D and L1580P were smaller than WT, while they both 
showed colocalization with CD63 (Fig. 8D). 
5.1.2 Incorporation of propargyl-Cho into phospholipids 
No quantification was conducted due to the reference standards for phosphatidyl-
propargyl-Cho was not available. Results showed that only WT cells treated with 
propargyl-Cho contained relevant signals of labeled lipids species as given in Figure 
9. For diacyl-phosphatidylcholines, mass transitions were observed in PC.aa.C34.1, 
PC.aa.C34.2, PC.aa.C32.1, and PC.aa.C32.0 et al. (Fig. 9A). The signals of LPC were 
within the range of blanks and untreated cells, thus incorporation into LPC cannot be 
Figure 9. Mean peak areas of propargyl-Cho labeled lipids. (A) Phosphatidylcholine 
labeled with propargyl-Cho. (B) Acyl-lyso-phospholipids labeled with propargyl-Cho. (C) 
Sphingomyelins labeled with propargyl-Cho. cps: counts per second.  
  
A. 
 
B. 
 C. 
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proven (Fig. 9B). While for another group of choline head phospholipid, subspecies of 
sphingomyelin were found propargyl-Cho incorporated (Fig. 9C).  
The results of phosphatidylcholines (Fig. 10) showed that WT cells treated with 
propargyl-Cho contained slightly less phosphatidylcholines than untreated cells, in 
both PC and SM group. Signals of LPC were barely detected, but LPC.a.C16.0 and 
LPC.a.C18.1 in treated cells were less than untreated. In propargyl-Cho treated cells, 
the mass transition of labeled PC was observed (Fig. 11A), e.g. PC.aa.C32.1, 
PC.aa.C34.1, and PC.aa.C34.2 et al. Further, cells treated with propargyl-Cho for 24 
Figure 10. Mean peak areas of choline head lipids. (A) Phosphatidylcholine. (B) Acyl-
lyso-phospholipids (C) Sphingomyelins.  Choline head lipids were analyzed in WT cells 
treated with or without propargyl-Cho. The injection and flow rate for different samples 
were the same. 
A. 
 
B. 
 
C. 
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h were conducted with click reaction and visualized with confocal microscopy (Fig. 
11B). Fluorescence intensity was uniform inside of ABCA3+ vesicles in focus, 
meanwhile labeled lipids could be observed outside of vesicles. Lipids signal did not 
overlay in the nucleus area. These results showed that propargyl-Cho was 
incorporated by WT cells successfully.  
Figure 11. Transfected A549 cells successfully incorporated propargyl-Cho. (A) Lipid 
spectrum. WT cells were treated with (lower panel) or without (upper panel) propargyl-Cho.  
Upper: phosphatidylcholine. Lower: phosphatidyl-propargyl-Cho. Examples of labeled 
phosphatidylcholine were marked by arrows. Cps: counts-per-second. PIS: precursor-ion-
scan. (B) Confocal microscopy. TAMRA-PEG3-Azide marked phosphatidyl-propargyl-Cho 
by click reaction with the extra alkynyl under Cu (II). Immunostaining of ABCA3-HA 
protein defined ABCA3+ vesicles. Scale bar: 5µm. The figures are cited from Li. Y et al. 
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Considering cell bio membranes are mainly composed of choline phospholipids, 
and that lipids fluorescence signal was observed outside of ABCA3+ vesicles, we 
examined the colocalization of propargyl-Cho labeled lipids with other membrane 
structures (Fig. 12). After immunostaining of ER (marker: calnexin), early endosome 
(marker: EEA1) and Golgi apparatus (marker: GM130), colocalization of phosphatidyl-
propargyl-Cho with these membrane structures were observed occasionally (white 
arrow).  
To ensure the choline analogue is not toxic, WT ABCA3 cells treated with 125 µM 
propargyl-Cho were monitored cell viability from 4 to 24 h with XTT assay. Compared 
to untreated cells, the absorbance of treated cells was at the same range at each time 
point (Fig. 13).  
Figure 12. Distribution of propargyl-Cho labeled lipids. Instead of ABCA3-HA, 24 h 
after pulse-labeling cells were stained with the Calnexin, EEA1 and GM130. Colocalization 
of referenced sub organelles was marked with white arrows. Scale bar: 5µm.  The figures 
are cited from Li. Y et al. 
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5.1.3 Incorporation of propargyl-Cho in an ATP dependent manner 
To elucidate the incorporation and transportation of propargyl-Cho into our cell 
model were based on positive consumption of ATP instead of passive diffusion, cells 
after pulse-labeling were treated with the ATPase inhibitor orthovanadate for 2 h. After 
inhibition, fluorescence intensity of propargyl-Cho labeled lipids inside of ABCA3+ 
Figure 13. Toxicity of propargyl-Cho. WT cells were seeded in phenol red free RPMI 
medium supplemented with 10% FCS in 96 well plates and incubated overnight. After pulse-
labeling, cells were treated with XTT solution with 100 mM PMS and measured absorbance 
at 4, 8, 12 and 24 h. Results were from 3 independent experiments. The figures are cited 
from Li. Y et al. 
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vesicles reduced to 22.5% of untreated cells, and intensity outside of vesicles 
decreased to 4.9% (Fig. 14A, B). The percentage of filled vesicles decreased to 46.6% 
(Fig. 14C). Treatment with orthovanadate did not affect the vesicle volume (Fig. 14D).  
5.1.4 Incorporation of propargyl-Cho was concentration dependent 
In the concentration dependent experiments about propargyl-Cho incorporation, 
cells were treated with increasing concentration of propargyl-Cho diluted in OptiMEM, 
then incubated cells in OptiMEM for another 24 h. Hence the experiment was 
conducted with the same concentration of choline (which was in OptiMEM). With higher 
concentration of propargyl-Cho, the fluorescence intensity in ABCA3+ vesicles 
improved nonlinearly (Fig. 15A, B). When treated with 10 or 250 µM propargyl-Cho, 
the fluorescence intensity between inside and outside of vesicles were at the same 
level. While treated with 50 or 125 µM propargyl-Cho, lipids inside vesicles were higher 
than outside (Fig. 15C). After 24 h, 100% of selected vesicles were filled up with 
labeled lipids in 125 µM, while only 64% in 50 µM. Therefore 125 µM was set for 
sequential experiments.  
5.1.5 Incorporation of propargyl-Cho was time dependent 
Cells in µ-slides were pulse-labeled with 125 µM propargyl-Cho for 30 min then 
incubated in OptiMEM for distinct time periods. Lipids piled up in ABCA3+ vesicles 
from 0 to 48 h gradually. Individual ABCA3+ vesicles encompassing massive labeled 
lipids could be observed since 24 h (Fig. 16A). When observe the time curve of lipids 
incorporation, the high-speed interval was between 12 to 24 h (Fig. 16B). Conspicuous 
Figure 14. Incorporation of propargyl-Cho in an ATP dependent manner. (A) Confocal 
microscopy of cells with or without inhibition of orthovanadate. -V, without orthovanadate. 
+V, with orthovanadate. Scale bar: 5 µm. (B) Fluorescence intensity inside and outside of 
vesicles before and after ATPase inhibition. (C) The percentage of filled vesicles. (D) 
Relative vesicle volume. Volume of treated cells were compared to untreated. The figures 
are cited from Li. Y et al. 
Results 
 48  
intensity difference between inside and outside of vesicles appeared after 12 h. At 24 
h, fluorescence intensity inside vesicles was nearly 2 folds of that in outside (Fig. 16C). 
Figure 15. Incorporation of propargyl-Cho was concentration dependent. (A) The 
precondition of the experiment was set as increase concentration of propargyl-Cho while stable 
concentration for choline. Fluorescence intensity in red channel sharped while the 
concentration of propargyl-Cho multiplied. Scale bar: 5 µm. (B) Lipids intensity inside 
vesicles relative to the intensity at 250 µM. The lipids intensities were 6.8%, 34.1% and 60.4% 
of the intensity at 250 µM when treated with 10, 50 and 125 µM respectively. (C) Fluorescence 
outside of vesicles increased in the same trend as inside. Outside of the vesicles, intensities 
were 38.2% and 36.6% of inside while treated with 50 and 125 µM propargyl-Cho. (D) All 
selected vesicles contained labeled lipids while treated with 125 or 250 µM propargyl-Cho. 
(E) Relative vesicle volume to untreated. *P < 0.0332, **P < 0.0021, **** P < 0.0001. The 
figures are cited from Li. Y et al. 
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Approximately 17% of selected vesicles contained propargyl-Cho labeled lipids at 6 h, 
57.5% at 12 h and 100% at 24 and 48 h (Fig. 16D).  
Figure 4
i ii iii iv v
A. 0 h 6 h 12 h 24 h 48 h
re
l.
 I
n
te
n
s
it
y
/f
il
le
d
 v
e
s
ic
le
P
e
rc
e
n
ta
g
e
 o
f 
fi
ll
e
d
 v
e
s
ic
le
s
 (
%
)
re
l.
F
lu
o
re
s
c
e
n
c
e
 
in
te
n
s
it
y
/µ
m
3
re
l.
 V
o
lu
m
e
Time (hour)
B.
D.
C.
E.
outside
inside
1
Figure 16. Incorporation of propargyl-Cho was time dependent. (A) Confocal images of 
WT cells treated with 125 µM propargyl-Cho for distinct duration. Massive lipids 
encompassed in ABCA3+ were arrow marked (iv). Scale bar: 5 µm. (B) Time curve of lipids 
incorporation. Intensities were relative to intensity at 48 h. (C) Relative fluorescence 
intensity/µm3 inside and outside of vesicles compared to outside intensity at 48 h. Before 24 
h, the intensity of in and outside of vesicles were of the same scale. After 24 h, the intensity of 
outside was only half the amount of intensity inside. (D) After 24 h, 100% selected vesicles 
encompassed labeled lipid. (E) Volume of vesicles was steady over time. The figures are cited 
from Li. Y et al. 
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5.1.6 Competitive inhibition phosphatidyl-propargyl-Cho transport  
Figure 17. Competitive inhibit phosphatidyl-propargyl-Cho transportation of 
ABCA3. (A) Experiment design for MLF inhibition. The time after pulse-labeling was set 
as time 0. Cells were incubated for continuous 24 h (0 – 24 h) or washed out after first 12 h 
(0 – 12 h). Another group of cells were treated with MLF from 12 to 24 h (12 – 24 h). (B) 
Confocal microscopy recording the lipids intensity alteration after MLF treatment. Scale 
bar: 5 µm. (C) Relative fluorescence intensity/µm3 inside vesicles compared to untreated 
cells. Either MLF worked on the cells 0 – 24 h, 12 -24 h or 0 – 12h, the lipids intensity 
reduced compared to untreated. (D) MLF on the cells for 24 h reduced the number of vesicles 
encompassed with propargyl-Cho labeled lipids. (E) Volume of vesicles was not affected. 
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We adopted Miltefosine (MLF), which was reported to be a substrate of ABCA3 in 
human macrophages [134] to treat WT cells after pulse labeling. Miltefosine was 
incubated with cells from 0 to 24 h, 12 to 24 h or washed out after 12 h (Fig. 17A). After 
treatment, the intensity of propargyl labeled lipids decreased in the cells in all 
circumstances (Fig. 17B). When incubated with MLF in the next 24 h after pulse 
labeling, the intensity of labeled lipids in the vesicles decreased by 67.5% from nt, and 
only 63.9% of analyzed vesicles contained labeled lipids. Washing out of MLF after 12 
h resumed the filled vesicles percentage to 98.6% and the fluorescence intensity to 
73.6% of nt. If MLF inhibition was applied to cells 12 h after labeling, filled percentage 
was not affected but the intensity in vesicles decreased by 26.6% (Fig. 17C, D). MLF 
treatment did not influence the cell viability (data did not show) or the vesicle volume 
(Fig. 17E). 
5.1.7 Irreversibly inhibition of phosphocholine synthesis by MN58b 
The first reaction in phosphatidyl-propargyl-Cho biosynthesis is catalyzed by 
choline kinase: ATP delivers a phosphate group to propargyl-Cho and forming 
phospho-propargyl-Cho. We inhibited the choline kinase of pulse-labeled cells from 0 
to 24 h, 0 to 12 h or 12 to 24 h with MN58b, a reported CK inhibitor [6, 135] (Fig. 18A, 
B). The presence of MN58b on cells from 0 – 24 h reduced labeled lipids in ABCA3+ 
vesicles by 67.3%. Unlike Miltefosine, washing out of MN58b at 12 h did not enhance 
the lipids amount inside vesicles (0 – 12 h vs. 0 – 24 h). Nevertheless, when the 
catalytic function of choline kinase was not inhibited in the first 12 h after pulse-labeling, 
the lipids intensity and filling percentage were not influenced (nt vs. 12 – 24 h) (Fig. 
18C, D). In each condition, volume of vesicles was not affected by the presence of 
MN58b. 
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Figure 18. Irreversibly inhibit the phosphocholine synthesis by MN58b. (A) 
Experiment design for MN58b inhibition. (B) Confocal microscopy of the lipids 
fluorescence intensity changes after MN58b treatment. Scale bar: 5 µm. (C) Relative 
fluorescence intensity/µm3 inside vesicles. Compared to untreated cells, treatment with 
MN58b for 0 – 24 h and 0 – 12 h reduced lipids intensity to 32.7% and 40.3% separately. 
(D) MN58b treatment reduced 31.1% vesicles encompassed with propargyl-Cho labeled 
lipids (0 – 24 h). (E) In each condition, volume of vesicles was not affected by the presence 
of MN58b. 
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5.1.8 Deviation of transport function of p.N568D and p.L1580P ABCA3 mutation 
Figure 19. Deviation of transport function of p.N568D and p.L1580P ABCA3 mutation. 
(A) Confocal microscopy of mutants treated with propargyl-Cho and incubated for different 
time period. Scale bar: 5 µm. (B) Propargyl-Cho incorporation time curve of WT and 
mutants. The ratio was compared to the fluorescence intensity inside WT ABCA3-HA at 48 
h. Difference of intensity appeared after 12 h. (C) Comparison of the outside and inside 
intensity among WT and mutants. (D) Either in mutations or WT, almost 100% analyzed 
vesicles contained labeled. (E) Mutants vesicle volume were smaller but consistent at each 
time point. The figures are cited from Li. Y et al. 
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After we proved that transporting of labeled lipids into vesicles was ABCA3 
dependent and that the transport process mainly happened 12 h after pulse-labeling, 
we tried the method on two patients originated mutations of ABCA3, p.N568D and 
p.L1580P. Both mutations were reported to undermine ATPase function of ABCA3 [61, 
82]. After outlined the time curve of propargyl-Cho labeled lipids incorporation of these 
two mutations, it showed both the speed and amount of incorporation decreased 
compared to WT (Fig. 19A, B). Intriguingly, the difference only appeared after 12 h 
when the transporting process happened. While analyzing the lipids intensity at 24 h, 
intensity inside p.N568D and p.L1580P ABCA3+ vesicles were 77.4% and 77.8% of 
WT. However, the intensity outside of vesicles were similar among WT and mutations 
(Fig. 19C). The vesicle filling percentage of p.L1580P was lower than WT before 24 h 
but reached 100% at 48 h (Fig. 19D). The vesicle volume of these two mutations were 
smaller than WT (Fig. 19E).  
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5.2 Lamellar body isolation 
5.2.1 Separation lamellar bodies by sucrose gradient 
After 4 h of consecutive ultracentrifuge, successful isolation of lamellar bodies was 
verified by western blot. While the same amount of protein was added, intensity of 
ABCA3-HA band in the lane fraction 3 to 5 were higher than other fractions. Condensed 
ABCA3 in F3 to 5 was observed compared to PNS (Fig. 20A, B. Red curve) while the 
protein concentration in PNS was almost 150 times higher than in F3 to 5 (Fig. 20B, 
black curve). ß-Actin was reduced in ABCA3 positive fractions. 
5.2.2 Intactness of fractionated lamellar bodies 
Figure 20. Isolation of lamellar bodies by sucrose gradient. (A) For Western blot analysis 
the same amount of total protein was added. ABCA3-HA and ß-actin was blotted with 
related antibodies. (B) Each fraction was analyzed for protein concentration by Bradford 
assay. Intensity of ABCA3-HA band was analyzed by ImageJ. Fraction 3 to 5 contained the 
most abundant ABCA3 protein (red curve) and rather low total protein concentration (black 
curve) compared to other fractions. The band intensity in all the fractions were compared to 
fraction 1 (F1).  
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To prove the intactness of isolated lamellar bodies, cells were incubated in 100 nM 
lysotracker red for 1 h before ultracentrifuge. After fixation and blocking with 
immunofluorescence buffer without saponin, LTR colocalized well in ABCA3+ vesicles 
(Fig. 21A, i-iii). While permeabilized of LBs with 1% Triton-X100 or saponin, LTR in 
ABCA3+ vesicles almost vanished (Fig. 21A, iv, v). In fractions 3 to 5, vesicles around 
1 µm diameter size were found LTR positive (Fig 21B).  
5.2.3 Purity of fractionated lamellar bodies 
To prove the purity of isolated LBs, 16.25 µl of each fraction was mixed with SDS 
buffer and blotted with marker proteins of other organelles. In F1 to F5, band of ß-Actin 
was reduced or disappeared. In F7 to F10 and PNS, the marker of early endosome 
Figure 21. Intactness of fractionated lamellar bodies. (A) After incubation with 100 nM 
LTR for 1 h, ABCA3-HA was stained with HA antibody diluted in immunofluorescence 
buffer without saponin (i – iii). Fluorescence signal of LTR decreased after permeabilized 
with 1% Triton-X100 or saponin for 10 min (iv, v). Scale bar: 5 µm. (B) After 
ultracentrifugation, fractions 3 to 5 contained intact lamellar bodies when assessed under 
confocal microscope. Scale bar in large figures: 10 µm. Scale bar in zoomed in figures: 5 
µm. 
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EEA1 was positive among WT and mutant cells. In post-nuclear supernatant (PNS) 
mitochondria marker Stoml2 was positive, as in fractions F6 to F10 for L1580P, while 
in fractions F1 to F5, no contamination of other organelles existed.  (Fig. 22). 
 
  
Figure 22. Purity of fractionated lamellar bodies. Western blot of sub organelle markers 
in fractions of WT, N568D and L1580P. The sample volumes applied to all the lanes were 
the same. Magnitude of ABCA3-HA signal (LBs) differed between expressed variants. Peak 
ABCA3-HA expression was in F5-F7, whereas variants N568D and L1580P had fewer 
signals and peaked in F6, F7 and higher, demonstrating poor separation of LBs from ß-actin 
and EEA1.  
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6 Discussion 
The present thesis describes a novel approach to study metabolism and trafficking 
of lipids in cells expressing the ABCA3 transporter, which represents as a new avenue 
to assess structure-function relationships of this important membrane protein, crucial 
in the biogenesis of pulmonary surfactant.  
We expressed wild type and hypomorphic variants of ABCA3 in A549 epithelial 
cells, to probe mechanisms for observing transport activity, and rectifying diseased 
alleles in a cellular setting. To quantify function of ABCA3 alleles, we employed the 
choline analogue propargyl-Cho. Propargyl-Cho was taken up by A549 cells and 
converted to the corresponding phospholipid via the enzymes involved in PC synthesis. 
The resultant phospholipids can be detected using a combination of click chemistry, 
fluorescence derivatization and microscopy to visualize and quantify the phospholipid 
end product.  
In the study we showed that propargyl-Cho signal was detected in lamellar bodies, 
endosomes (early and late), and endoplasmic reticulum. At high concentrations it also 
can be detected in the cytoplasm. The accumulation or detection of labeled 
phospholipids was ATP-dependent by using ATPase inhibitors. The detection of signal 
was dependent on choline kinase to incorporate the label into cellular phospholipids. 
Another substrate of ABCA3 can compete with the transport of propargyl-Cho by 
ABCA3. Finally, we showed that mutations (p.N568D and p.L1580P) in the ATP-
binding cassette of ABCA3 impaired transport function of propargyl-Cho into 
intracellular vesicles. This method described a new labeled phospholipid that will allow 
researchers to probe phospholipid handling and transport in more detail. 
In the conventional studies of pulmonary biology, the radioactive analogues of 
choline were most frequently used. Treating isolated alveolar II cells or cell model with 
[methyl-3H] choline for a certain time period and measure the radioactive intensity or 
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electron microscopic radioautography unraveled principles of pulmonary PC synthesis. 
For example, a quantitative time study of feeding choline-deficient mice with [methyl-
3H] choline showed that the radioactive PC precursor exclusively accumulated in type 
II cells when observed with electron microscopy [31]. In ATII cells, [methyl-3H] choline 
labeled lipids and [3H] leucine label amino acids first appeared in the ER then in Golgi, 
MVBs and were eventually stored in LBs, indicating the synthesis and traffic routine of 
lipids and protein of surfactant. This was further verified by Osanai K et al. by culturing 
cells with [methyl-3H] choline or [35S] methionine/cysteine in the presence of the Golgi 
apparatus disassemble agent, brefeldin A. After lipids extraction, immunoprecipitation 
and LBs fractionation, it was demonstrated that only surfactant protein transport was 
a Golgi-dependent act. On the contrary, lipids transport in ATII cells was through a 
Golgi-independent pathway [32]. Continuing signal decrease of [methyl-3H] choline 
labeled lipids suggested ongoing secretion and turnover of LBs [136]. In 1975, 
scientists found in cortisol treated human fetal lung tissue that the intensity of [methyl-
3H] choline labeled phosphatidylcholine increased with the number of lamellar bodies, 
which suggested that in early ages cortisol could increase the surfactant production 
[137].  
Figure 23. Literatures with ‘[3H] choline’ in PubMed. By searching for the key word 
‘[3H]’ choline in PubMed, we found the number of literatures contained in this field 
increased yearly from 1968 to 1991, then decreased gradually to only 1 or 2 literatures per 
year. Data was from NCBI. 
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However, with the emerging appearance of new non-radioactive choline 
analogues and tough barriers to entry radioactive experiments around the world (Fig. 
23), researchers turned to employ more environment-friendly analogues. Among 
commercially available fluorescence PC analogues, one category is 7-nitro-2-1,3-
benzoxadiazol-4-yl (NBD) labeled lipids such as NBD-PC, PE, PS, SM, ceramide and 
cholesterol. Although the NBD-lipids were only discovered a few decades ago, they 
are the first choice to study the biology of membrane [138]. For example, C6-NBD-PC 
was extensively utilized in studying the dynamics of DPPC bilayer [139, 140]. In the 
study of Weichert N et al., C12-NBD-PC and C12-NBD-PE were observed to colocalize 
with WT ABCA3+ vesicles under confocal microscope, but not with p.R43L, p.L101P 
and p.R280C mutated ABCA3 [141]. However, the number of colocalization of NBD 
lipids with ABCA3 was few, not to mention to understand the dynamic, or quantity of 
ABCA3 transport function.  
Another fluorescence analogue of lipids is BODIPY labeled phospholipid. In 
microalgae, BODIPY 505/515 was a rapid, practical and non-expensive choice for 
neutral lipids staining [142-144]. To study the removal of DPPC/dioleoyl 
phosphatidylcholine (DOPC) from mineral surface by microphages, Das AR et al. used 
BODIPY labeled DPPC* to coat quartz or kaolin particles and realized the removal of 
DPPC* or DOPC was independent of the mineral specific characteristics [145]. Other 
studies chose BODIPY stained SP-B protein rather than lipids to elucidate the 
biogenesis or function of surfactant [146-148]. Thus, to understand the phospholipids 
transport function of ABCA3, neither NBD nor BODIPY labeled lipids are good choices. 
In 2009, Jao CY et al. synthesized a choline analogue named propargyl-choline to 
metabolic label choline containing phospholipids in cultured cells and animals [130]. 
Unlike radioactive choline analogue or NBD-/BODIPY- lipids, propargyl-Cho is a non-
radioactive and rather small analogue that supposed to participate in the biogenesis 
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pathway of choline. In NIH 3T3 cells, after 24 h culture and click reaction with 
Alexa568-azide, propargyl-Cho was found to be efficiently and intensely incorporated 
into Cho group phospholipids. Either in plasma membrane or intracellular structures, 
the staining of propargyl-Cho could be visualized. There were no signs of cellular 
toxicity when the concentration of propargyl-Cho reached as high as 500 µM. With 
electrospray ionization-tandem mass spectrometry (ESI-MS/MS) assay, propargyl-
Cho was found to incorporate efficiently into all Cho head phospholipids. The ratio of 
labeled Cho was in accordance with the increasing concentration of propargyl-Cho. 
18% and 33% of Cho was replaced by propargyl-Cho when labeled with 100 and 250 
µM propargyl-Cho separately. Thus, this method provided a clear and convenient way 
to study the biology of choline and choline phospholipids in vitro and in vivo. 
Propargyl-Cho – azide fluorophore click reaction method described Jao CY et al. 
was then applied in various studies. Luo Z and collogues established an optical 
imaging method to monitor the choline change when cancer cells were treated with a 
chemotherapy reagent, cisplatin [149]. In the study, click reaction of propargyl-Cho 
happened with Alexa-488 azide. The fluorescence of labeled Cho phospholipids 
decreased as the concentration of cisplatin increased. Luo Z et al. then applied this 
method on isolated head and neck cancer biopsies and found the intensity of labeled 
lipids was observed to be 4 or 5 fold higher compared to control tissues [150], which 
provided an alternative pathological diagnosis method for physicians. Propargyl-Cho 
was also used in another lipid enriched cells – neuro system to assess the myelin 
remyelination in animal multiple sclerosis model [129]. In the central neural system of 
the tested animal model, newly synthesized myelin could be visualized and quantified 
through propargyl-Cho labeling. With this method, the authors found glatiramer acetate 
could promote the remyelination in experimental autoimmune encephalomyelitis. 
Beside in mammalian cells, propargyl-Cho was also used in plants and Streptococcus 
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pneumoniae to clarify the biological characteristics of choline phospholipids in these 
species [151, 152].  
In the present study, the behavior of propargyl-Cho shared similarities with the 
aforementioned studies. Successful incorporation of propargyl-Cho into ABCA3 
expressing A549 cells was confirmed by both confocal microscopy and lipids mass 
spectrometry. Same as the results from Jao CY et al., three species of choline head 
phospholipids, phosphatidylcholine, lysophosphatidylcholine and sphingomyelin were 
labeled with propargyl as shown by mass spectrometry. Similarly, the concentration 
dependent incorporation of the analogue was non-linear. This is in accordance with 
our observation of a 5-fold increase of propargyl-Cho concentration only resulted in 
2.9-fold increase of fluorescence intensity in ABCA3+ vesicles (250 µM vs. 50 µM).  
With long exposure time, the fluorescence signal of propargyl-Cho in cells treated 
with a high concentration (1 mM) could be detected 30 min after treatment, while under 
short camera exposure, the time course was 3 to 6 h [130]. In our study, the fluorescent 
labeled lipids could be observed 6 h after pulse labeling, the signal kept stably 
increasing until 48 h, which conform to those experiments conducted with radioactive 
[3H] choline, indicating a similar behavior of propargyl-Cho in A549 cells to natural 
choline [153, 154].  
To investigate whether propargyl-Cho transporting across the plasmatic 
membrane and among sub organelles occurred in an ATP dependent active transfer 
or a passive transfer manner, we inhibited the ATPase of cells by sodium 
orthovanadate (NO3VO4). NO3VO4 is a common ATPase inhibitor utilized to study the 
function of ABC transporters [155-157]. In this study, after NO3VO4 treatment the 
amount of lipids decreased both in and outside of ABCA3+ vesicles, suggesting the 
transport of propargyl-Cho was an ATP dependent active but not passive transfer.  
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To eliminate the interference of background lipids intensity, which was unavoidable 
since phospholipids was necessary components of bio membranes, we took several 
conductions. First, we verified the colocalization of propargyl-Cho labeled lipids with 
other intracellular structures such as ER and early endosomes. Then, during each 
independent confocal microscopy, the pinhole, laser power, digital gain and offset for 
each image and Z-stack were set properly to avoid noise and high background. With 
all the measures set already as above the fluorescence signal outside of ABCA3+ 
vesicles were still visible. Therefore, we analyzed the intensity outside of vesicles to 
help interpreting the results.  
In the time dependent experiments intensity of labeled lipids outside of vesicles 
increased synchronously with the intensity inside, however, the disparity between in 
and outside only appeared after 12 h. 12 h was also a watershed that the lipids intensity 
inside WT ABCA3+ vesicles was higher in mutant ABCA3+ vesicles after but not before. 
In A549 cells and ATII cells from rat, the incorporation of [methyl-3H] choline into PC 
could be observed as soon as 60 min after labeling [158]. In the study of Voelker DR 
et al., the saturated DPPC in the LB fraction increased gradually in the first 8 h after 
chasing with radioactive choline for 20 min [159]. While the desaturated PC activity in 
LBs increased steadily in the first 12 h after administration of [methyl-3H] choline [160]. 
It is plausible that the synthesis of propargyl-PC in the vesicles mainly happened from 
initial point to 12 h.  
To ascertain this speculation, we chose two time points (0 and 12 h) to expose 
cells to MN58b. Without interfering the function of other enzymes of De novo synthesis 
pathway such as CTT, CHPT or PAP, MN58b specifically targets choline kinase and 
decreases the synthesis of phosphatidylcholine [135]. Exposure to MN58b supposed 
to significantly decrease the uptake of choline at certain dose, causing ER stress and 
triggering apoptosis of cancer cells [6, 135, 161-163]. The working concentration of 
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MN58b in A549 cells was 10 µM, which exhibited no cell toxicity and inhibited PC 
synthesize irreversibly. Intriguingly, the inhibition only worked when cells were exposed 
to MN58b for the first 12 h (either washed out or not), but not after 12 h. Thus, it is 
proved that the PC accumulated in LBs in 24 h was mainly synthesized in the first 12 
h, which was in accordance with the results from [3H] choline labeling experiments 
[158-160].  
In the study of visceral and cutaneous leishmaniasis, Dolmen LC et al. found that 
when infected human macrophages exposed to Miltefosine (hexadecyl 
phosphocholine), an alkylated phosphatidylcholine as the only licensed oral medical 
treatment for the parasite, ABCA3 transporter expression on cell membrane was highly 
induced. During the antileishmanial process, the role of ABCA3 was to impede the 
treatment by transport MLF out of macrophages, while knockdown of ABCA3 by 
shRNA reduced leishmanial survival [134]. The authors concluded that ABCA3 on the 
membrane of macrophages act as MLF efflux transporter. As a predict competitor of 
propargyl-Cho labeled PC transported by ABCA3, MLF treatment decreased the 
labeled lipids in LBs in the present study. The inhibition was partially released after 
washing out of MLF at 12 h.  
However, interpretation of the results in MLF inhibition should be rather careful. In 
a Langmuir monolayer model mimicking natural cell membrane, MLF interacted 
strongly with cholesterol in the monolayer rather that phosphatidylcholine [164]. And in 
HepG2 cells MLF hampered cholesterol trafficking to ER and reduced the synthesis of 
PC [165]. By comparing the [3H] choline uptake in control and MLF treated cells, Geilen 
C et al. proposed that the translocation of choline phosphate cytidyltransferase (CHPT) 
was inhibited by the phosphocholine analogue [166]. The influence of MLF on the 
phospholipid’s membrane stability and lipids homeostasis thence cannot be ignored.  
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Combining the results from MN58b and MLF inhibition experiments, we recognized 
that the fluorescence intensity of labeled lipids inside ABCA3+ vesicles at 24 h was an 
index of specific ABCA3 choline-head phospholipids transport function. To further 
confirm the guess and make the propargyl-Cho assay applicable, we described the 
same time curve of propargyl-Cho incorporation curve from two reported functional 
mutations of ABCA3, p.N568D and p.1580P. cDNA variate from A to G at 1702 site in 
ABCA3 lead the missense mutation of  p.N568D, which was first found in a patient 
(compound heterozygous) who died after lung transplantation and described by 
Shulenin S et al [93]. In the same study, p.L1580P (c. 4739T>C) was identified in a 
patient (homozygous) who died in the neonatal period of life. The asparagine inside 
Walker A motif mutated to aspartic acid, disturbing the conserved structure of 
nucleotide binding domain 1 of ABCA3. Although L1580P just ‘located close to NBD2’, 
side-chain size change and potential helix break contribute to the impaired ATP 
hydrolysis. Other mutations in the transmembrane domain (T1114M, G1221S) of 
ABCA3 may cause aberrant function of the protein although the exact mechanism was 
not clear [61, 87]. Matsumara Y et, al. found the ATP binding capacity of N568D and 
L1580P decreased to 60% and 54% of WT, which resulted in an ATP hydrolysis by 
N568D and L1580P was 12 and 9% of that of WT protein. Vanadate-induced 
nucleotide trapping partially explained the loss of NBDs function of ABCA3, but the 
direct impact of the variants’ influence on the phospholipids transport function was not 
measured. In our study, the phosphatidyl-propargyl-Cho transport function of these two 
mutations were quantified. Compared to WT ABCA3, the total amount lipids 
accumulated in LBs of p.N568D and p.L1580P ABCA3 decreased dramatically, 
indicating the loss of transport function of these mutations. These results suggested 
that propargyl-Cho assay is a practical tool to characterize the function of newly 
identified ABCA3 mutation and to assist find new treatment strategy of related disease.   
Discussion 
 66  
The phospholipids transport function of p.N568D and p.L1580P were also 
characterized in a previous study by TopF-PC assay with a similar analyzing strategy 
[87]. The results of TopF-PC assay showed that the transport activity of p.N568D and 
p.L1580P decreased to 14% and 10% of WT separately, while propargyl-Cho assay 
showed the reduction of transport function were 77% and 78% of WT. There was a 
study indicating that in rat ATII cells the uptake of [3H] choline labeled natural surfactant 
was much higher than synthetic phospholipids liposomes, and the difference increased 
with culturing time [167]. Thus, the distinguished transport function measured by TopF-
PC (synthetic phospholipids liposomes) and propargyl-Cho (natural surfactant) could 
be explained. The short comes of TopF-PC were discussed in part 1.1.5 and in our 
published paper [168]. Except for the difference associated with the theory of the label 
into the cell system, there were many similarities between these two methods: 
incorporation of these two reagents was time, concentration and ATP dependent 
transportation. Considering that up to date propargyl-Cho assay is limited usage on 
fixed cells only, while TopFluor lipids are utilized in live cell imaging [169-171], we 
expected that the combination of these two methods will together open the possibility 
of additional insights into the biogenesis and transport of surfactant lipids.  
We characterized a new functional assay of ABCA3 utilizing propargyl-Cho, and in 
previous studies we found correctors and potentiators that were potential treatments 
for ChILD patients [87, 114, 168]. Despite phosphatidylcholine, lipids such as 
cholesterol and phosphatidylglycerol may also play important roles in surfactant 
biology. Novel methods to measure the transport function of other lipids of ABCA3 
await to be established. In this effort, we tried to isolate LBs in WT ABCA3 expressing 
A549 cells for further lipidomic analysis. With the classical sucrose gradient 
fractionation method [172-174], we isolated LBs successfully. Lamellar bodies 
distributed mainly in fractions 3 to 5 with high purity. Isolated LBs from p.N568D and 
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p.L1580P also existed in fraction 5. LBs are now prepared for lipidomic analysis. Due 
to the complexity, massive labor and materials requirement of sucrose gradient 
isolation, combining specialties of LBs and fluorescence activated flowcytometry 
sorting of sub organelles might help to isolate LBs efficiently [175-177].  
Although applying propargyl-Cho to isolated type II cells would definitely benefit 
the study, we do not have a source for isolated human ATII cells. Regarding that the 
genotype of A549 cells and primary ATII cells are different from each other, an altered 
model could be human induced pluripotent stem (IPS) cells with and without mutations. 
Another problem related to primary cell is the lack of availability of ABCA3 antibodies 
which can reliably label this protein in the ATII cells. Although the use of A549 cells as 
an ATII cell model has several limitation [178, 179], lamellar bodies like structures were 
expressed by transfection with ABCA3 [83, 131]. Recently, it was reported that air-
liquid interface (ALI) culturing of A549 cells induced a more ATII cell-like phenotype, 
such as SP-C expression and thyroid transcription factor-1, and the morphology 
analysis showed A549 cells reconstituted epithelial layers in ALI [180, 181]. ALI 
culturing could be a choice to study the function of secretion of surfactant lipids by LBs 
in ATII cells in the future.  
In conclusion, we applied an interesting method to interrogate ABCA3-dependent 
lipid transport in living cells. We expressed wild type and mutants of ABCA3 in A549 
epithelial cells, to probe mechanisms for phospholipids transport activity with a choline 
analogue followed by click reaction for visualization. In general, A549 cells do not 
closely resemble alveolar type II cells, but their application in this study provided a 
facile method to study ABCA3 related functions. 
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